Browse Month: May 2017

CPR Pharma Services #canadian #pharma

#cro pharma

#

Welcome to CPR Pharma Services

CPR Pharma Services ( CPR ) is a full-service CRO with an international reputation for delivering superior clinical trial results in Australia, New Zealand and Asia through our Fast2PhaseOne and Access2Asia services.

As the premier provider of early phase clinical trial services in the Asia-Pacific region for over a decade, we have leveraged our extensive experience to now offer an expanded range of services. CPR can assist you to:

  • Get your trial underway quickly and cost effectively via our Fast2PhaseOne service
  • Confidently navigate entry into the Asian market via our Access2Asia service
  • Provide bioanalytical support in the Asia-Pacific via our FDA-inspected laboratory in Australia
  • Access the Australian Government s attractive R D Tax Incentive through our strategic partnership with one of Australia s leading taxation experts
  • Get your trial back on track through our Recovery Centre .

Please peruse our website to learn more about CPR and our team of experts. or contact us directly to discuss your specific requirements.

Get it right first time with CPR the experts in early phase clinical research.

FDA Audit – Complex peptide no challenge for CPR scientists

With the in-life component of a clinical trial completed, a large multinational pharmaceutical company approached CPR to help develop a peptide assay to complete the bioanalysis to report data before an FDA deadline closed.

New Ligand Binding Assay Service – CPR expands APAC offering with large molecule analytical service

CPR s new laboratory, in Adelaide, Australia now offers best practice ligand binding assay services for biomarkers, monoclonal antibodies, biosimilars and biologics in early and late phase clinical trials the first APAC based laboratory to offer such an extensive range of GLP services.





Management Team – Pharma Start #pharmaceutical #business

#cro pharma

#

Management Team

“We are committed to high quality deliverables and optimal patient treatment, by providing a personal investment in each project that we take on.”

As the founder of Pharma Start, Dr. Christina Fleming provides the company’s strategic direction by leveraging her 20+ years of biopharmaceutical and Clinical Research Organization (CRO) industry experience. Dr. Fleming’s experience includes building, managing and leading Clinical Development, Medical Writing, and Pharmacovigilance Divisions at Searle (formerly Pharmacia, now Pfizer), TAP (now Takeda), Neopharm Inc, and Baxter Healthcare as well as developing the outsourcing/CRO consulting services at several CROs. This experience led her to create and develop Pharma Start into a highly successful and unique outsourcing organization. Dr. Fleming is a 2010 recipient of PharmaVoice’s Top 100 Most Inspiring People in the Life Sciences Industry award and is a member of DIA, AMWA, and RAPS. Dr. Fleming earned her Bachelor of Science (BS) in Biology at Saint Mary’s College and her Doctor of Philosophy (PhD) in Pharmacology from the University of Illinois at Chicago.

” ‘Winging It’ is not a project plan; communication, foresight, and flexibility create project success.”

Marcy Komocsar has over 15 years of pharmaceutical, device, and biotechnology experience. Marcy’s career includes positions of increased responsibility in the safety and medical writing departments at Searle (Pharmacia, now Pfizer), Allos Therapeutics, Takeda (TAP) Pharmaceuticals, and Baxter Healthcare. In 2006, Marcy transitioned to the outsourcing and CRO space, directing Medical Writing groups. At Pharma Start, Marcy leads a team of writers, editors, and document specialists who have finalized >25 NDAs/505(b)(2)s, and hundreds of CSRs, peer-reviewed journal articles, manuscripts, abstracts, and conference posters. Marcy’s team of professionals has a high rate of FDA approval and dossier acceptance. Marcy is a graduate of Indiana University School of Nursing and a current member of the Drug Information Association (DIA), Women in Bio, the National Association of Professional Women, and the American Medical Writers Association (AMWA).

“Constant learning is a must in this global quality and regulatory landscape.”

Thomas McGrady has 25+ years of experience in Quality and Regulatory in the pharmaceutical, biotechnology, and medical device industries. Tom has served in QA/RA leadership roles at the plant, divisional, and corporate levels at companies such as Astellas US, Baxter Healthcare, and completed project work for companies such as Abbott Laboratories, Cardinal Health, and Pharmacia. He is highly experienced in GxP regulations, technology, and system validation and possesses expertise in the development and management of global quality systems. Tom earned his Bachelor of Science (BS) in Microbiology from Purdue University and his Master of Business Administration (MBA) in Finance from the University of Illinois (Chicago).

“I enjoy bridging the gap between science and medicine. “

Dr. Paulson has over 25 years experience in the pharmaceutical industry and contributed to submissions of numerous sNDAs, NDAs and INDs for both large and small molecules including Celebrex and HUMIRA. Her work has resulted in numerous publications and several patents. Dr. Paulson was most recently Director of Clinical Pharmacology and Pharmacometrics at Abbott Laboratories. Prior to Abbott, she held positions in Clinical Pharmacology and Drug Metabolism at NeoPharm and Searle/Pharmacia. She is an adjunct professor in the Department of Pharmacology and Biological Chemistry at Northwestern University Feinberg School of Medicine





Welcome to Thinq Pharma – CRO Ltd #novartis #pharma #ag

#cro pharma

#

ABOUT THINQ

THINQ Pharma is an integrated pharmaceutical company with broad global presence and world class products and services.
Head Quartered in Singapore and having a fully equipped Research Centre in Mumbai, India, we have served the global market for over 25 years
With a highly skilled team, we provide comprehensive solutions in the pharmaceutical and wellness industries.

Products

We have the technology for developing varied formulations and an efficient regulatory affairs team designed for market compliance.

THINQ is one of the few pharmaceutical companies that are vertically integrated with API and Formulations segments. Our API business is committed to deliver high quality products to the market.

With R
/* 728×90, создано 05.02.11 */
google_ad_slot = “6127977750”;
google_ad_width = 670;
google_ad_height = 90;
//–>

PM Society – Pharmaceutical Marketing Events, Education, Networking and Training #medicinal #chemistry

#pharmaceutical marketing

#

Digital: The third Digital Works Meeting brought together nine experts from industry and the NHS who had something to say about “how digital works”. Read what they had to say in our full report.

Digital Media Awards: Read about the Digital Awards ceremony on April 27th 2016. Find out which agencies and pharma companies came out on top.

Digital Media Awards: View the full online results brochure here, including information on this year s judges, sponsors, the event and all the award winners.

PM Society Market Access Interest Group Meeting 18th July 2016

New PM Society advocates list announced

Two New Executive Committee Appointments

Client Development for Agencies

PM Society Patient Engagement Interest Group

PM Society Committee Meeting, 7 June 2016, ABPI Offices, London

The PM Society seeks to promote marketing excellence throughout the healthcare and life science industries, promising to educate, inform and facilitate networking through its various channels – online, print and at live events.

Twitter





SteriPack Drives Pharmaceutical Packaging Growth – Blister Packaging #pharma #science

#pharmaceutical packaging companies

#

  • PL + 48 71381 8199
  • MY + 60 33167 3596
  • US + 1 863 648 2333

SteriPack Malaysia Drives Pharmaceutical Packaging Growth

SteriPack s facility in Malaysia ensures that the group can offer state of the art blister packaging services all over the globe.

SteriPack is a worldwide packaging solutions provider, serving the medical device and pharmaceutical industries. Since its foundation in 1994, the company has invested significantly by building its processes and quality systems to extremely high standards throughout its facilities located in Ireland, Poland, Malaysia, and the US.

In recent times, SteriPack s facility in Asia has specialised in pharmaceutical opportunities, with pharma now accounting for 50% of its business exports to over 52 countries. The facility, which is located in Klang, Selangor, Malaysia, has been extended in recent months, expanding its pharmaceutical packaging services within its new purpose built cGMP compliant Grade D facility, assisting pharmaceutical and allied healthcare companies who require outsourced blister packaging services. “Companies from the pharmaceutical and healthcare sector have to comply with very strict safety rules,” explains John Ward, Managing Director SteriPack Malaysia. “As well as ensuring the best protection of the drugs and allowing full traceability, the contribution of the packaging to greater efficiency and cost reduction has become a major factor.”

The SteriPack Malaysia MD believes that “the days of air freighting finished product all over the world are starting to end”. This is where SteriPack have a huge advantage: “The ability to be able to offer state of the art packing facilities in Asia is a major attraction for our global customers.”

For SteriPack, demand for Blister Contract Packaging continues to grow amongst their pharmaceutical client base. “We have plans to expand our pharmaceutical packaging service offerings in 2013 to allow for bulk bottle filling, powder filling and liquid filling, all within a cGMP environment,” Ward noted. “This extra facility will be fully operational by January 2014.”

SteriPack also provide a wide range of cleanroom manufactured barrier foil packaging solutions to the pharmaceutical industry. SteriPack s focus is to provide customers with a responsive, can-do attitude to almost any pharmaceutical packaging request.

COMPANY HISTORY

SteriPack are recognised globally as an industry leader in providing medical packaging solutions and contract services. Since its inception 19 years ago, the group has grown steadily, with manufacturing facilities now located in Ireland, Poland, Malaysia and the USA.

Their ISO Class 8 cleanroom production facilities house all manufacturing capabilities, ensuring that SteriPack remain at the very highest levels of quality and service at all times.

The group s head office of SteriPack Group is located in Clara, Co. Offaly, while the US business, specialising in flexible medical packaging and contract manufacturing service solutions, is based in Lakeland, Florida.

SteriPack Poland was established in 2006 to serve customers in central and eastern Europe. Specialising in contract manufacturing services, the company is located in Jelcz-Laskowice, Poland. SteriPack Asia was established in 2008 and operates a 8,500 square metre facility in Malaysia.





WPP Group buys CMI healthcare and pharma media agency #pharmaceutical #sector

#pharma agency

#

WPP Group buys CMI healthcare and pharma media agency

Adding to its healthcare heft, WPP Group bought CMI, a healthcare media agency that counts 10 of the largest 20 pharma advertisers among its clients.

CMI will not be absorbed into the group, but rather work across WPP healthcare agencies, which include Ogilvy CommonHealth, Sudler Hennessey and Greyhealth Group. CMI will subsume Ogilvy CommonHealth’s medical media unit and be housed under WPP’s healthcare parent hub GroupH. It will also work closely with WPP media holding company GroupM.

In fact, CMI has already co-pitched two clients with GroupM, and together they won both assignments, said Stan Woodland, CEO at CMI. WPP has owned a minority stake in Compas, the healthcare media buying company Woodland also presides over, since 2004.

John Zweig, chairman of healthcare and specialist communications at WPP, said his group was impressed with the differentiation CMI has in the market, adding he hasn’t previously seen the “depth, sophistication and quality of targeting that CMI does.”

“When we combine it with the capabilities in Ogilvy CommonHealth, it’s an industry leading offer. Client relationships demonstrate that, both in longevity and in what they feed back as indispensability. When’s the last time you heard clients themselves describe an agency resource as indispensable?” Zweig said.

Consolidation in the agency world is nothing new, but it’s newer in healthcare specialty agencies. However, more overall agency mergers–and big healthcare M A–have resulted in larger relationships between the two sides, geographically and in a range of disciplines, Zweig said, which requires a correlating range of skill sets.

Adding to the mergers is the healthcare focus shift to patients, who are also consumers. That’s where WPP’s global consumer strengths can bolster CMI’s healthcare provider expertise, Woodland said. CMI itself has proven its ability to collaborate with both small and large agencies, he said, and the deal expands its reach across the WPP agencies and clients it doesn’t already serve.

Zweig said, “What beyond the pill really means is you now have to surround the patient with value-creating information and services that are tailored to that patient. That’s where I think the combination of media targeting can not only improve the message, but in the healthcare business, should be able to improve the quality of the therapy because information is part of it,” he said.

Terms of the deal were not disclosed. WPP is the largest global marketing communications holding company, with billings of $73 billion and revenue of $19 billion. CMI reported unaudited revenues of $38 million as of the end of 2015 and employs more than 210 people. CMI clients include Amgen ($AMGN), Bayer, Biogen ($BIIB), Eli Lilly ($LLY), Johnson Johnson ($JNJ) and Novartis ($NVS).





API Generic Manufacture #www.buy-pharma.com

#api pharma

#

Active Pharmaceutical Ingredients (API)

Aesica has been engaged in the manufacture of generic APIs for over 30 years and, combined with our development and supply services, we have the facilities and expertise to take an API from pre-clinical all the way to commercial scale manufacture.

We’re a global leader in API generic manufacture in areas such as non-steroidal anti-inflammatory (NSAID’s) products, antidepressants and anaesthetics, and all our generic APIs are manufactured according to cGMP and appropriate regulatory frameworks (MHRA, FDA, PDMA, CEP, etc.). Our focus on operational excellence and continuous improvement ensures our processes are efficient and effective.

As part of our complete end-to-end API generic manufacture solution, we offer a systematic, tried and tested approach to technology transfer overseen every step of the way by our dedicated project managers and experienced technical teams.

THE WHOLE SUPPLY CHAIN. SIMPLIFIED.

How Aesica can add value at every stage

Finished dose development Finished dose manufacture API development

Contact Us

Got a question or specific requirements? Just ask.

Bespak

For further information on Device Development please visit Bespak.

Consort Medical

For further information on our Group vision and values please visit Consort Medical plc.

Learn more

Technology Transfer

Continuous Improvement

Generic APIs





Small cap pharma stocks: Latest News – Videos, Photos about small cap pharma stocks #pharma

#small pharma companies

#

SMALL CAP PHARMA STOCKS

10 small cap stocks which caught the fancy of fund managers

Despite rich valuations, fund managers have kept buying these shares with the hope that they will outperform in the long run.

4 Aug, 2016, 12.30AM IST

China stocks close lower as regulatory clampdown knocks small caps

The CSI300 index of the largest listed companies in Shanghai and Shenzhen.

29 Jul, 2016, 11.58AM IST

Seven stocks to look at from small-cap universe

It has been observed that investing in companies with improving financials and low price-earn.

16 Jun, 2016, 05.13AM IST

Stocks in news: Bharti Airtel, Sun Pharma

The Indian market is expected to open higher tracking positive trend seen in other Asian markets.

18 Aug, 2016, 08.59AM IST

Rally takes promoters of small-cap companies past the $1 billion mark

The average stock return of these five companies has been almost seven times higher than the BSE Small Cap index over the past two years.

16 Aug, 2016, 11.30AM IST

All about stocks: SBI and Sun Pharma

After closing on the highs, markets are expected to open and perform better in the coming week. Watch this video to know the stocks that are expected to give good returns and prove to be safe bet for retail investors.

13 Aug, 2016, 09.19AM IST

When Rakesh Jhunjhunwala took stock of his investment in Aurobindo Pharma

In terms of opportunity, we do not see more than three-four players getting into that. So that is the level of opportunity which exists.

24 Aug, 2016, 10.36AM IST

Don’t see sugar prices coming down with cap being put on stock holding: Abinash Verma, ISMA

Abinash Verma said that government’s restriction would affect only 50-60 sugar mills and not the whole industry.

2 Sep, 2016, 09.57AM IST

Personal finance corner: Small cap rally to stay?

In a chat with ET Now, Dhirender Kumar of Value Research talks about the small cap rally and how long will it be staying.

1 Jul, 2016, 03.12PM IST

Stocks to buy: Jain Irrigation, PNB, Reliance Cap

ET Now spoke to various experts and here’s what they have to recommend for today’s trade.

28 Jul, 2016, 09.11AM IST

Stocks to buy: Grasim, Dishman Pharma, Jindal Steel

ET Now spoke to various experts and here’s what they have to recommend for today’s trade.

2 Aug, 2016, 08.40AM IST

Stocks to buy: Reliance Cap, United spirits

In a chat with ET Now, experts recommends stocks for the day’s trade for the investors.

26 Jul, 2016, 08.51AM IST

What’s in store on D-Street: Bank stocks likely to gain, IT & pharma may correct

Traders should take calculated risk as now if market finds hurdle then sector and stocks churning cannot be ruled out, suggest experts on Dalal Street.

29 Aug, 2016, 08.26AM IST

Experts re-rate pharma stocks post weak Q1 show

After the first-quarter earnings, the once bullish analysts are re-rating stocks of Dr Reddy s, Lupin and Cipla. We tell you why.

17 Aug, 2016, 08.17AM IST

​Double-digit topline growth in Q1, but m-caps down by one-third! Are these stocks good buys?

Data available with corporate database Capitaline showed these stocks belong to pharma, textiles and IT packs and also include a few credit rating agencies.

19 Aug, 2016, 01.29PM IST

#LeanIn: Maternity Bill passed in RS, now women to get 6 months off

While India was rooting for PV Sindhu, Andhra Pradesh and Telangana were googling her caste

The wait is over: iPhone 7 is coming soon

Centre returns bill for 400 per cent hike in Delhi MLA salaries

Price war: Idea, Vodafone and Bharti Airtel to slash tariffs to compete with Reliance Jio

Can football help you build your portfolio?

‘No chance’ of returning to the family business, says Onida Group’s Sasha Mirchandani

Best 13-inch laptops of the year

How to permanently erase data from an Android device

An IAS officer got a call from PM Narendra Modi at 10 PM and this is what happened next

Smartphones which are compatiable with Reliance Jio

Digvijay Singh terms Kashmir ‘India-occupied Kashmir’

Reliance Jio data plan tariffs: All you want to know

Cyclical mutual funds: Running the relay of business cycles profitably

I spent my first salary on candies: Sunny Leone

5 smartphones likely to launch this week

US immigration debacle over, SRK takes selfies with fans at son’s film school

Air India Express turns profitable for the first time

Poll





Pharma CRM #pharma #consulting #companies

#pharma crm

#

Join our team

Pharma CRM

Pharma CRM:

PSTech company’s Pharma CRM is an improvement in pharmaceutical company services aimed at customers through recognition of their needs.

Indications

It is well-known that the competition on the market of pharmaceutical products fights not only for patients, but for doctors as well. Being familiarized with sales and marketing processes of pharmaceutical companies and mega drugstores, PSTech company has included specialized software solution to its portfolio. The solution is based on powerful Sugar CRM platform which fully complies with marketing/sale needs of pharmaceutical companies and mega drugstores.

Pharma CRM application

PSTech company’s pharmaceutical CRM from provides:

  • Effective and efficient automation of sale process,
  • Dynamic marketing directed at medical and pharmaceutical experts – doctors, nurses, pharmacies and distributors.

Pharma CRM is simple to install and is easily adapted towards specific business needs and expert terminology of a company.

Effects

  • Reduced sale expenses and significantly increased productivity of associates on field,
  • Quick and efficient response to medical expert inquiries,
  • Supports RX and OTC medicines.

Increase your revenue from the existing products and prepare the market for the upcoming offers

Please contact us for more information





About us – Member Companies #verona #pharma

#pharmaceutical research companies

#

About us Member Companies

The vfa, the Association of Research-Based Pharmaceutical Companies (vfa), is the trade organization of research-based pharmaceutical companies in Germany. 45 leading research-based pharmaceutical companies are organized in the vfa. Together with their more than 100 subsidiaries and affiliated companies, they employ nearly 80,000 people in Germany.

The vfa members represent more than two-thirds of the entire German pharmaceutical market. The vfa member companies are among the leading research-based pharmaceutical companies worldwide. They guarantee therapeutic progress in pharmaceuticals and ensure high-quality pharmaceutical therapy.

In Germany more than 18,000 of their employees work in the field of research and development of pharmaceuticals. Here, the research-based pharmaceutical companies invest EUR 5.2 billion per year in pharmaceutical research. The Association of Research-based Pharmaceutical Companies represents a German high-tech industry that is competitive in the international markets.

The Pharmaceutical Industry in Germany

Germany: The Perfect Location for Research, Production and Sales – a publication by GERMANY TRADE INVEST and vfa
Brochure Download





Abbott Laboratories Company Information #pharma #consulting #companies

#drug manufacturer

#

Abbott Laboratories

Latest Drug Information Updates

  • Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent.
  • Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated.
  • Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the.
  • Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A.
  • Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB).
  • Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing.

More.

Was this page helpful?

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Support

About

Terms Privacy

Connect

Subscribe to receive email notifications whenever new articles are published.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated Aug 9th, 2016), Cerner Multum (updated Aug 1st, 2016), Wolters Kluwer (updated Aug 8th, 2016) and others. To view content sources and attributions, please refer to our editorial policy .

We comply with the HONcode standard for trustworthy health information – verify here

Copyright 2000-2016 Drugs.com. All rights reserved.





Pharmaceutical – Medical Sales Recruitment Agencies #acceleron #pharma

#pharma agency

#

Scientific Pharmaceutical Recruitment Agency

Industry Specialization

Spectrum Staffing Services is a top pharmaceutical recruitment agency, serving clients and candidates in NY, NJ, NC, and across the country. Our pharmaceutical sales recruiters and medical sales recruiters specialize in placing qualified candidates into rewarding career opportunities with top employers. Spectrum provides the following industries with Contract, Contract-to-Hire, Direct Hire and RPO staffing services:

  • Consulting and Engineering Design Industry
  • Pharmaceutical Industry
  • Medical Device Industry
  • Bio/Medical Industry
  • Scientific/Laboratory Industry
  • Research and Development
  • Life Sciences Industry
Scientific Pharmaceutical Jobs We Place

Spectrum places scientific and business professionals in many of the following careers:

  • Regulatory Affairs
  • Quality Control
  • Scientists
  • Drug Safety
  • Chemists
  • Quality Assurance
  • Packaging
  • Product Development
  • Packaging Design

If you re a candidate looking for scientific or pharmaceutical job opportunities, or an employer seeking out talented professionals, the staffing experts at Spectrum will get you on the right track. Contact us today to learn more about our pharma recruitment services.





Alliance Contract Pharma – Manufacturing and Lab Services #nexgen #pharma

#contract pharmaceutical manufacturing

#

Welcome to Alliance Contract Pharma

Alliance Contract Pharma is a leader in providing value-added services to our customers by creating a successful partnership with them throughout their project. Our pledge is to establish lasting relationships with our customers by exceeding their expectations and gaining their trust through exceptional performance.

Alliance Contract Pharma has been privately owned since 2008 and has 70 years of combined experience in the pharmaceutical industry with an emphasis on contract manufacturing and laboratory services. We provide clinical and commercial product development, contract manufacturing, packaging and laboratory services for the pharmaceutical industry. Learn more about us .

Manufacturing Services

Our manufacturing services include Liquid Filled Capsules, Powder Filled Capsules, Over Encapsulation, and more. Learn more about our manufacturing services .

Laboratory Services

Our laboratory services include Raw Material, Release Testing, Method Development Validation and Evaluation, and more. Learn more about our laboratory services .

Alliance Contract Pharma Facility

Our facility is in Harleysville, PA, conveniently located 2 miles off the Pennsylvania Turnpike at Exit 31, Lansdale and about 50 minutes Northwest from the Philadelphia Airport. We have a 30,000 square foot facility. To learn more and to get started, contact us or request a quote .

Our Mission

Alliance Contract Pharma is a leader in providing value-added services to our customers by creating a successful partnership with them throughout their project. Our pledge is to establish lasting relationships with our customers by exceeding their expectations and gaining their trust through exceptional performance by every member of the ACP team.

Our Values

Our customers improve the quality and longevity of people s lives. It is our privilege to contribute to this great mission.





Pharmaceutical companies in houston tx #solvay #pharma

#pharmaceutical companies in houston tx

#

div.slide” data-cycle-swipe=”true” data-cycle-swipe-fx=”scrollHorz” data-cycle-fx=”fadeout” data-cycle-log=”false” data-cycle-pager=”.cycle-pager” data-cycle-delay=”4000″ >

The Perfect Blend of Qu ality and Inno va tion

Bringing together shared industry experience for best practice, enhancing our partners ability to provide superior patient outcomes.

When It Comes To Quality Testing, We Don t Skip Batches.

The quality of our product is of paramount importance and we won t send anything to you that hasn t been fully tested to USP standards. Your colleagues and patients deserve to know they are receiving the best medicine every time, without exception.

Unparalleled Service That Anticipates Our Customers Needs

Partnering with customers to collaborate on risk mitigation, waste reduction, and service enhancement opportunities where QuVa brings a unique concept of industry best practice.

Reduction of Medication Errors Through Precise Teamwork and Highly Controlled Environment

QuVa s operations are an extension of yours. We have specialty facilities, staffed by cGMP experts, doing specific tasks in a purpose controlled environment, all supported by layers of independent verification and final product testing. Together we are unrivaled.

Free Yourself from Prep Time

Partnering with QuVa can provide you the additional qualified resources you need to move the pharmacy department into value adding activities associated with clinical outcomes. Let QuVa prepare those readily anticipated products with our experienced staff and dedicated facilities and systems, and you explore the ocean of opportunities to improve patient care.





LOG – pharmaceutical packaging companies – About US #robinson #pharma

#pharmaceutical packaging companies

#

LOG Ltd. Is a leading Pharmaceutical packaging manufacturer founded in 1971 in Israel.

As results of growing sales in the European market, LOG GmbH, a daughter company was established in the center of Germany and began manufacturing in 2006.

LOGs‘ mission is to create value for its customers with exciting packaging solutions, offers a challenging environment that encourages excellent for its employers and plays a responsible role in the community. With over 35 years of experience in International regulation compliance, quality cost effective manufacturing according to standards, and innovative new product development, we are well positioned to continue to be at the forefront of packaging technology in the future.

Innovative products developed together with Drug manufacturers include the BnB (Bottle in a bottle), HW (Heavy wall) and ML (Multilayer bottles with barrier) series, and enhance LOGs‘ standard packaging solution for the Pharmaceutical market.

LOG is dedicated to servicing our client‘s needs. With an extensive product base to build on, LOG offers clients the opportunity to develop a unique product, customized to their specifications.
While LOG remains a leader in innovative solutions, we continue to offer high volume standard production. Our valuable resources of knowledge and experience allow us to ensure our customers are best placed in their particular markets.

Kibbutz Ashdot Ya`acov, Jordan Valley 1515500, Israel,

LOG-PLASTIC PRODUCTS COMPANY (1993) LTD.





Top 20 Healthcare Packaging Companies 2014: Leaders in Pharmaceutical and Medical Devices #pharmaceutical #science #jobs

#pharmaceutical packaging companies

#

Top 20 Healthcare Packaging Companies 2014: Leaders in Pharmaceutical and Medical Devices

LONDON. Dec. 2, 2014 /PRNewswire/ — Report Details
Visiongain assesses that the healthcare packaging market is highly fragmented with the top 20 companies accounting for just 32% of the global healthcare packaging market in 2014.

The healthcare packaging market still has vast potential. In a global, interconnected economy, where the ease and immediacy of social interactions make the world a smaller place, such trends are also having an impact on how brands communicate with their consumers. As the global healthcare packaging market adapts to regional shifts on the demand and supply side, the future of the industry will be different, allowing for growth opportunities. Globally, changing attitudes towards climate change, together with recent developments in medical technology, will provide new sources of demand growth. In the Asia-Pacific region, increased drug production and infrastructure development will dominate growth. Outsourcing and medical tourism will support further growth opportunities.

Who are the top 20 healthcare packaging producers? Visiongain’s comprehensive new report contains detailed analyses of the leading 20 healthcare packaging companies with the key facts of each company’s revenue, market share, strategies focus and outlook.

How this 120 page report will inform you:

– View extensive profiles of the leading 20 companies in the healthcare packaging market to keep your knowledge ahead of your competition and ensure you exploit key business opportunities
– The report provides detailed sales of the market and the commercial drivers and restraints allowing you to more effectively compete in the market. Our study shows current market data, market shares, original critical analysis, and revealing insight into commercial developments.

– The report provides 68 tables, charts, and graphs
– Let our analysts present you with a thorough assessment of the current healthcare packaging market. This analysis will achieve quicker, easier understanding. Also you will gain from our analyst’s industry expertise allowing you to demonstrate your authority on the healthcare packaging sector.

– View 2 exclusive expert company interviews. Visiongain is one of the few business intelligence companies that provides full transcripts of primary research company interviews. Learn what industry thought leaders are thinking.
– By reading the full transcripts of exclusive expert opinion interviews contained in the report you will keep up to speed with what is really happening in the industry. Don’t’ fall behind.
– Mr. Tim Marsh. Managing Director of Marsh Consulting
– Mr. Mike Codington. Managing Director of Chesapeake Pharmaceutical Packaging

– Discover sales for the top 20 healthcare packaging companies
– What are the prospects for the top 20 healthcare packaging companies? How is the market evolving? Which company generates the most revenue? Use our study and expert insight to grow your business and give you more industry influence. Stay informed about the potential for each of these healthcare packaging market with individual analysis 2014.

– Explore the factors affecting product developers, and everyone within the value chain. Learn about the forces influencing market dynamics.
– Explore the strengths, weaknesses, opportunities and threats (SWOT) and Political, economic, social and technical factors (PEST) affecting the industry and product advances. Discover what the present and future outlook for business will be. Learn about the following business critical issues –
– Technological issues
– Emerging markets
– Market regulations and standards
– Disposal issues of healthcare packaging
– Anti-counterfeiting issues.

– Identify who are the leading 20 companies in the healthcare packaging industry
– Our report reveals the companies which hold the greatest potential. In particular, exploring and analysing the activities of these companies: See where the expected gains will be. Our work explains that potential, helping you stay ahead. Gain a thorough understanding of the competitive landscape with profiles of 20 leading healthcare packaging companies examining their positioning, capabilities, product portfolios, services, focus, strategies, M A activity, and future outlook.
– Adelphi Healthcare Packaging Ltd.
– ALPLA
– Amcor
– Ardagh
– Becton Dickinson
– Bemis
– Berry Plastics Corporation
– Catalent
– Clondalkin Group
– Gerresheimer
– Graphic Packaging Corp.
– MeadWestvaco Corporation (MWV)
– Mondi
– Multi Packaging Solutions(MPS)/Chesapeake
– Owens- Illinois (O-I)
– Rexam
– Schott Pharmaceutical Packaging
– Sealed Air
– West Pharmaceutical Services
– WiPak

Discover Information found nowhere else in this independent assessment of the top 20 healthcare packaging companies
Top 20 Healthcare Packaging Companies 2014: Leaders in Pharmaceutical and Medical Devices report provides impartial healthcare packaging sector analysis. With the independent business intelligence found only in our work, you will discover where the prospects are for profit. In particular, our new research provides you with key strategic advantages: independent and objective analysis, exclusive interviews and revealing company profiles will provide you with that necessary edge, allowing you to gain ground over your competitors.

With this report you are less likely to fall behind in knowledge or miss crucial business opportunities. You will save time and receive recognition for your market insight. See how you this report could benefit and enhance your research, analysis, company presentations and ultimately your individual business decisions and your company’s prospects.

What makes this report unique?
Visiongain’s research methodology involves an exclusive blend of primary and secondary sources providing informed analysis. This methodology allows insight into the key drivers and restraints behind market dynamics and competitive developments. The report therefore presents a comprehensive analysis of the top 20 healthcare packaging companies including revenue, market share, products, services, strategy focus and outlook.

Why choose visiongain business intelligence?
Visiongain’s increasingly diverse sector coverage strengthens our research portfolio. The growing cross-sector convergence of key verticals and the interplay of game changing technologies across hitherto unrelated industries are creating new synergies, resulting in new business opportunities for you to leverage.

As such, visiongain’s team of London based in-house analysts offer a wealth of knowledge and experience to inform your strategic business decisions. Let visiongain guide you.

How the Top 20 Healthcare Packaging Companies 2014: Leaders in Pharmaceutical and Medical Devices report can benefit you
Visiongain’s report is for anyone requiring analysis of the healthcare packaging market. You will discover market analysis, technological trends and expert opinion providing you with independent analysis derived from our extensive primary and secondary research. Only by purchasing this report will you receive this critical business intelligence revealing the market position of each top player in the healthcare packaging industry and where the lucrative potential market prospects are. Don’t miss this key opportunity to gain a competitive advantage.

If you buy our report today your knowledge will stay one step ahead of your competitors. Discover how our report could benefit your research, analyses and strategic decisions, saving you time. To gain an understanding of how to tap into the potential of this market and stay one step ahead of the competition you must order now our report the Top 20 Healthcare Packaging Companies 2014: Leaders in Pharmaceutical and Medical Devices. Avoid missing out order our report now.

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com





Drug company R – D: Nowhere near $1 billion #www.buy-pharma.com

#drug research companies

#

Drug company R D argument for half a century, but the specific source of the $1 billion claim is a 2003 study published in the Journal of Health Economics by economists Joseph DiMasi of Tufts, Ronald W. Hansen of the University of Rochester, and Henry Grabowski of Duke. I will henceforth refer to this team as the Tufts Center group, because they were working out of the (drug-company-funded ) Tufts Center for the Study of Drug Development. The Tufts Center group “obtained from a survey of 10 pharmaceutical firms” the research and development costs of 68 randomly chosen new drugs and calculated an average cost of $802 million in 2000 dollars. That comes to $1 billion in 2011 dollars based on the general inflation rate since 2000 (28 percent). One billion dollars for every little orange prescription bottle in your medicine cabinet! And according to PhRMA, even that is way too low! As of 2006, its calculation of the drug-development average had already risen to $1.32 billion. That means costs specific to drug development increased by 64 percent between 2000 and 2006. Medical inflation typically outpaces general inflation, but PhRMA’s calculation puts its rate of cost increase at more than twice the rate for medical inflation during that period (26 percent). If Pharma’s alleged inflation rate hasn’t slackened since 2006, then the drug-development average should be now approaching $2 billion. But let’s not go there. We’ll stick to Big Pharma’s official last-stated estimate of $1.32 billion.

The new study, by sociologist Donald W. Light of the University of Medicine and Dentistry of New Jersey and economist Rebecca Warburton of the University of Victoria, and published in the journal BioSocieties. builds on some excellent previous research by journalist and health care blogger Merrill Goozner, author of The $800 Million Pill . and the consumer advocate Jamie Love. Light and Warburton begin by pointing out that drug companies submitted their R D data to the Tufts Center group on a confidential basis and that these numbers are therefore unverifiable. Light and Warburton find it a little fishy that only 10 of the 24 invited firms chose to participate, given “the centrality of the issue and the prominence of the Center” within the industry. “The sample,” they suggest, “could be skewed” toward companies or drugs “with higher R D costs.” Light and Warburton also observe that if the Tufts Center group made any effort of its own to verify the information it received from the drug companies, the group makes no mention of it in the study.

The first research phase involved in developing a new drug is basic (as opposed to applied) research. Very little of this type of research is funded by drug companies; 84 percent is funded by the government, and private universities provide additional, unspecified funding. The Tufts Center group assumed that drug companies spent, on average, $121 million on basic research to create a new drug, but Light and Warburton find that hard to square with their estimate that industry devotes only 1.2 percent of sales to all their basic research. Add in a few additional considerations and Big Pharma would have us believe basic research costs end up constituting more than one-third of the Tufts Center’s $802 million estimate. That’s way too much, Light and Warburton say.

Another problem Light and Warburton have with the Tufts Center group is that they didn’t subtract from their R D calculations pharmaceutical firms’ tax breaks. Research and development costs, they point out, are not depreciated over time like other investments; rather, they’re excluded entirely from taxable profits. This tax break lowers net costs by 39 percent. Add in other tax breaks and that cuts the Tufts Center group’s R D estimate in half.

Now take that figure and cut it in half again. Light and Warburton say, because half the Tufts Center group’s estimate was the “cost of capital,” i.e. revenue foregone by not taking the money spent on R D and investing it in securities instead. But R D is a cost of doing business, Light and Warburton point out; if you don’t want to spend money on it, then you don’t want to be a drug company. And who says that investing in securities always increases your capital? Sometimes the market goes down. Many of us learned that the hard way in 2008.

There are other problems. The Tufts Center group’s per-subject calculation of how much clinical trials cost was six times that of a National Institutes of Health study. Its calculation of how much time it takes to conduct clinical trials and have them reviewed by the Food and Drug Administration—7.5 years—is twice as long as Light and Warburton’s calculation, which is less than four years. The Tufts Center group’s use of the average (mean) cost rather than the median cost, Light and Warburton argue, is also misleading, because R D costs for different drug products vary widely, and a very few expensive drugs will skew the mean. That appears to have happened in this case, because the Tuft Center group’s median was only 74 percent of the mean.

When Light and Warburton correct for all these flaws—well, all the ones that can be quantified—they end up with an average cost of bringing a drug to market that’s $59 million and a median cost that’s $43 million. In 2011 dollars, that’s a $75 million average and a $55 million median.

So the drug companies’ $1.32 billion estimate was off, according to Light and Warburton, by only $1.265 billion. * Let’s call it a rounding error.

Correction, March 7, 2011: This article originally and incorrectly stated that the drug companies’ estimate was off by $977 million. (Return to the corrected sentence.)





Pharma software #pharma #resources

#pharma software

#

SOFTWARE THAT GIVES YOUR PHARMACY

THE COMPETITIVE EDGE

QS/1 offers the industry’s leading software platforms
to effectively manage independent, retail, chain and
long-term care pharmacies.

  • THE MOST COMPREHENSIVE HME PLATFORM IS ALSO

    THE AFFORDABLE SOLUTION

    SystemOne gives you the best tools that will fit your budget
    to run an HME business of any size.

  • LONG-TERM CARE PHARMACY JUST GOT

    PrimeCare is the LTC choice that is organized to
    meet any LTC pharmacy’s and facility’s needs.

  • QS/1 NEWS AND INFORMATION GIVES YOU

    Check out the digital edition of Insight magazine,
    QS/1’s quarterly publication 36 pages of
    industry news to keep you informed.

  • QS/1’S SOFTWARE SOLUTIONS ARE THE BUZZ OF

    PHARMACISTS LIKE YOU

    QS/1’s customers share the benefits of our pharmacy
    management systems click here for Customer Videos.

  • THE FUTURE OF
    PHARMACY IS LOOKING

    SharpRx packs productivity
    and profitability
    into one solution.

  • in Pharmacy Outpatient (Retail)

    QS/1 NRx: 2015/2016 Category Leader – Pharmacy Outpatient (Retail)
    2015/2016 Best in KLAS Awards: Software and Services Report

    The fastest way to grow your pharmacy with the leader in Pharmacy Software. Check out our products and features.





  • 143 Pharmaceutical Sales Representative Jobs in Houston, Texas #shionogi #pharma #inc

    #pharmaceutical companies in houston tx

    #

    Job Search Tips

    The ZipRecruiter job matching algorithm analyzes millions of jobs from hundreds of job boards to instantly return the most relevant results. Here are some additional tips to help you optimize your search:

    Job titles are best:

    Searching for a specific job title provides more accurate results than company names or other keywords. software engineer is better than coder. and registered nurse is better than hospital .

    Zip code can help narrow your location:

    For location, a zip code is generally more precise than entering city, state.

    You can use quotes:

    Surround multiple terms in quotes to treat them as a phrase, like: program manager or dental hygenist .

    You can exclude certain terms:

    Enter a minus sign before any terms you want to exclude, like: -travel or – entry level .

    You can require certain terms:

    Enter a plus sign before any terms you want to require, like: +full-time or + full benefits .

    143 Pharmaceutical Sales Representative Jobs in Houston, Texas





    100 Companies by Revenue Headliners #big #pharma #companies

    #health it companies

    #

    100 Companies by Revenue Headliners

    | Reprints


    While every company in the HCI 100 is making a strong mark in the field of healthcare IT, some stand out further than others. To be up for inclusion in our Headliners section, companies must first make that made the top 40 in our ranking. After that, we looked at vendors that have, for example, taken ownership in a particular niche, grabbed the reigns of a leading-edge technology, or been active in the M A realm by snapping up competitors.

    Selecting these companies was not easy. As there are so many worthy companies, competition was fierce, and editors fought for their favorites in closed-door meetings. But when all was said and done, we feel as if our 2007 Headliners represent some of the most outstanding leaders in the field – companies that don’t just do what their clients tell them, but suggest to their clients what to do.

    We trust you’ll enjoy our 2007 Headliners profiles. – the Editors

    Companies (Rank ) in the Healthcare Informatics 100 List





    Fastest Growing Pharmaceutical Companies #generic #pharmaceuticals #companies

    #small pharma companies

    #

    Fastest Growing Pharmaceutical Companies

    Updated August 17, 2016

    Some of the biggest innovations in the healthcare industry are being made by small pharmaceutical companies, some with fewer employees than a single department in one of the larger companies. By focusing on niche markets and therapeutic areas, these little companies are making a big impact for patients. From treating illnesses that affect only a handful of the population to focusing entirely on one disease state, these companies are showing how a targeted approach can get results.

    In addition to including some of the fastest growing traditional pharmaceutical companies, this list also includes several companies – mainly information technology enterprises – engaged in supporting pharmaceutical development and sales.

    Monty Rakusen/Getty Images

    US WorldMeds is a specialty pharmaceutical company based in Louisville, Kentucky. Its marketed products include treatments for malignant hyperthermia. cervical dystonia and hypomobility in Parkinson s disease. In its pipeline, it has a drug for reducing opiate withdrawal symptoms, a growing area of concern as opiates continue to be abused. More

    Elorac Inc., a specialty pharmaceutical company based in Vernon Hills, IL, develops and markets novel drug products for the U.S. dermatology and oncology drug markets. It has a topical psoriasis treatment on the market and received orphan drug status to develop a naloxone lotion for itching associated with T-cell lymphoma. More

    Pacira Pharmaceuticals, Inc.. located in New Jersey, is a niche pharmaceutical company developing non-opioid products for managing post-surgical pain. Products include DepoCyt(e) an injectable, sustained-release form of cytarabine for the treatment of lymphomatous meningitis and Exparel, a local analgesic. It also developed DepoFoam, a novel drug delivery method which encapsulates drugs and then releases them over a set time period ranging from 1 to 30 days. Its pipeline is especially promising considering the renewed focus in the medical community on automatic-release medications to reduce user error. More

    Putney. based in Michigan, is unique in that it focuses on creating high quality generic medications for pets. From pain relief medications to antibiotics, they produce drugs used in veterinarian offices around the country. More

    Vets First Choice. Portland, Maine, an online veterinary partner-pharmacy and marketing service provider, is the nation s fastest growing business services provider. It provides home delivery of FDA approved pharmaceuticals, therapeutic diets and compounded medications to pet owners on behalf of veterinary practices. More

    Clinipace Worldwide is a contract research organization (CRO) based in Morrisville, NJ, that conduct trials of experimental drugs for pharmaceutical and biotechnology companies. More

    Integrated Prescription Management. Fresno, CA, is a prescription benefit manager. It provides services for employers, third-party administrators and brokers. More

    Noble Rx Marketing of Orlando, FL, develops educational marketing materials geared for patients and healthcare professionals on behalf of biotechs and pharmaceutical companies. From disease state information to guides on how to use and administer treatment, Noble RX Marketing creates comprehensive materials to help both physicians and patients better utilize medications. More

    Greenphire. headquartered in King of Prussia, PA, develops and manages proprietary payment technologies for the clinical trial industry. An extremely competitive area, clinical trials are the focal point for many pharmaceutical companies, making Greenphire highly sought after. More





    Irish Pharmacy News #helvoet #pharma

    #pharmacy news

    #

    Welcome to IPN Communications

    Welcome to IPN Communications Ltd. an Irish based publishing company specialising in the Pharmacy sector of Ireland.

    Armed with the premier, most exciting pharmacy trade magazine in the country Irish Pharmacy News (IPN), the recently launched Hospital Pharmacy News (HPN), the yearly Irish Pharmacy Awards, the Pride in Product Awards and CPD we are constantly innovating and bringing you the best opportunity to understand how to improve your business.

    Quick Links

    Contact Us

    • DUBLIN OFFICE
      Office 36 Clifton House
      Lower Fitzwilliam Street
      Dublin 2

    Recent News

    A few months removed from the 2016 Iris
    Wed – 10 Aug

  • Apply now to be considered for the four
    Tue – 21 Jun

  • The IPN Pharmacy Representative of the
    Wed – 04 May

    Subscription List

    Oh no. This form doesn’t exist. Head back to the manage forms page and select a different form.





  • Qualitest Pharmaceuticals Company Information #pharmacutical #companies

    #drug manufacturer

    #

    Qualitest Pharmaceuticals

    Latest Drug Information Updates

    • Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent.
    • Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated.
    • Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the.
    • Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A.
    • Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB).
    • Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing.

    More.

    Was this page helpful?

    Drugs.com Mobile Apps

    The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

    Support

    About

    Terms Privacy

    Connect

    Subscribe to receive email notifications whenever new articles are published.

    Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated Aug 9th, 2016), Cerner Multum (updated Aug 1st, 2016), Wolters Kluwer (updated Aug 8th, 2016) and others. To view content sources and attributions, please refer to our editorial policy .

    We comply with the HONcode standard for trustworthy health information – verify here

    Copyright 2000-2016 Drugs.com. All rights reserved.





    Pharma Consulting, LLC #canada #pharma

    #pharma consulting

    #

    D2 Pharma Consulting LLC is a Life Sciences consulting firm comprised of accomplished industry professionals who provide hands on expertise in all aspects of channel management including commercialization, distribution and compliance activities from launch to life cycle management for pharmaceutical products and devices.

    D2 provides strategic and tactical expertise to emerging and existing pharmaceuticals, biotech, and specialty organizations focusing on the individual client s business objectives.

    D2 steam of consultants will provide the vision necessary to ensure your organization s success operating in an evolving marketplace environment.

    Our philosophy is to be a strategic partner with our clients based on trust, integrity and impeccable work ethic resulting in value add to our customers. Our motto is Excellence Through Teamwork.

    more info





    Pharmaceutical Distribution Software from IBS #pharmaceutical #representative

    #pharma software

    #

    Pharmaceutical Distribution Software

    Industry Trends

    The pharmaceutical market is in constant change, and the demand to continuously adapt expansive supporting systems is extreme. As companies grow through mergers, acquisitions and alliances, it becomes increasingly important to have a system that is easy to maintain in multiple facilities, locations, platforms, regions and languages.

    Pharmaceutical distribution places a heavy burden on the operational and logistics resources of any company. Industry-specific regulations and institutional requirements, forecasting, procurement, customer service, picking, dispatch and special treatment of physical inventory can all place a burden on logistical decisions. Add to that low margins, high customer service expectations, a constant fight against counterfeit medicines and global competitive pressures, and the margin for error is negligible.

    No wonder government monitoring and regulations have increased. As borders open up and generics increasingly flood in, consumers are beginning to buy direct, blurring industry lines between wholesale and retail distribution and straining the supply chain from the manufacturer down to basic provider levels.

    How do you manage this unwieldy and heavily monitored supply chain? How do you ensure rapid delivery of perishable and critical medicines while balancing compliance, customer satisfaction and profitability issues? Is your system up to the intense data and integration requirements it takes to be a world-class provider in this highly fragmented and ever-changing landscape?

    IBS can help. Our expertise in managing pharmaceutical distribution operations is long-standing and proven, providing the latest thinking in logistics for an industry that never stops moving.

    Business Drivers

    IBS specializes in pharmaceutical business software, matching a staggering amount of pharmaceutical wholesalers’ specific requirements out-of-the-box. It’s a distribution solution for fast implementation and integration worldwide.

    Using our deep, proven knowledge of the industry, we can help you tailor a customized solution specifically for your business that drives value, meets your organization where you are today and prepares you for where you want to go tomorrow.

        • Sales: Our integrated order entry system ties warehouse, logistics and invoicing to unique customer orders placed online, at a store or through your call center for accurate, traceable, controlled delivery and payment.
        • Procurement: Automate and optimize procurement processes across the supply network, based on accurate inventory forecasts to meet various order sizes, types, minimums and seasonal demands.
        • Warehouse management: Streamline warehouse activities, from goods reception and quarantines, to pick verifications, controlled substances and combined transport, using multiple shipping systems and paperless automation technologies.
        • Financials and accounting: Make any financial process easy-to-manage and totally transparent, including handling multiple simultaneous currencies.
        • Compliance: Rest assured having a defensible system that automates, captures and complies with your specific distribution requirements and regulations, including our unique, global “counterfeit compliance solution.”
        • Lot Tracking/Recall: Ensure reporting and data integrity, especially vital for FEFO (first end date first out) products, to assist with regulatory compliance and recall ability.
        • Complex Rebates and Chargebacks: Automatically track details for accurate sales management and accounting.

    IBS pharmaceutical clients include Galexis, Sigma, Panarello, Associated Pharmacies Inc, Marzam, Alloga, Drogueria Betances, Oriola, uniPHARM Wholesale Drugs, MWI Veterinary Supply, TopRX, Strategic Pharmaceutical Solutions, North Carolina Mutual Drug, Metro Medical, Sandvik Medical, Mediq, LLC Wholesale, Sunset Pharmaceuticals, and ICS/AmerisourceBergen to name a few.





    Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC #pharma #manufacturers

    #epic pharma

    #

    Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC

    The acquisition of Epic will provide a robust generic product portfolio which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic’s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of 37 products, and this acquisition will complement PuraCap’s own R D efforts by utilizing Epic’s strengths in the manufacture and development of controlled drug substances and powder formulations. The Epic acquisition will also add a US FDA DEA inspected GMP manufacturing footprint of 110,000 square feet in Laurelton, New York. and result in the addition of 215 employees to the Humanwell and PuraCap US Operations Team.

    Richard Wang. the Chairman of Humanwell Healthcare Group, stated that “This acquisition continues to broaden our global investments consistent with our strategy for the creation of a truly global pharmaceutical company for Humanwell Healthcare Group.”

    “This acquisition is a major step in the growth of our company. In addition to strong and growing OTC and Branded Business units in the US, this acquisition along with our recent acquisition of Blu Pharmaceutical LLC Blu Carib Inc. firmly establishes Humanwell and PuraCap in the US Generic Rx Pharmaceutical segment. The PuraCap US footprint continues to expand our tablet, softgel, 2-piece capsules, cream, and powder product portfolio,” stated Dahai Guo. CEO of PuraCap and also President of Humanwell USA LLC. “The addition of Epic is an important addition to the PuraCap family. We look forward to it being a platform for the development of our generic pharmaceutical business, both in the USA as well as internationally.”

    Under the terms of the agreement, the acquisition is subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, obtaining approval of Humanwell stockholders, obtaining various filing notices and registrations from certain governmental entities in the People’s Republic of China. and other customary conditions. The parties expect the transaction to close in the second quarter of 2016.

    China Merchants Bank New York Branch is the Bookrunner and Mandated Lead Arranger in this transaction. Nomura served as financial advisor and Fox Rothschild LLP served as U.S. legal counsel to Humanwell and PuraCap. Jefferies LLC served as financial advisor and Hughes Hubbard Reed LLP served as U.S. legal counsel to Epic.

    About HumanwellHealthcare Group

    Humanwell Healthcare (Group) Co. Ltd is a fully integrated life science company that focuses on investing, developing and managing healthcare companies. It was founded in 1993 and has been listed on the Shanghai Stock Exchange since 1997. With a market capitalization of US$3.5 Billion. it is recommended for its top investment value by institutional investors.

    Humanwell invests in companies who are leaders in anesthetics, CNS, reproductive biological medicines, herbal medicines, and diagnostics and medical devices in China. In 2015, Humanwell Healthcare Group achieved $1.6 billion in operating revenue, through both organic growth and expansion through acquisitions. Go towww.renfu.com.cn for more information.

    About PuraCap Pharmaceutical LLC

    PuraCap Pharmaceutical LLC isa New Jersey basedfully integrated pharmaceutical company with expertise in product development, manufacturing, and bringing affordable, world-class quality products to their customers. The PuraCap corporate structure supports a three-pronged approach for global growth with dedicated companies in the areas of prescription brands (PuraCap Pharmaceutical) as well as prescription generics and OTC and private label brands (PuraCap International LLC). PuraCap continues to innovate using soft gel expertise developing other soft gel and oral solid dosage options. Go towww.puracap.com for more information.

    This news release includes forward-looking statements. Some examples of forward-looking statements include statements regarding the timing and closing of the Epic acquisition, the ability of Humanwell and PuraCap to complete the Epic acquisition considering the various closing conditions, and any assumptions underlying the foregoing. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Risks and uncertainties include general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which PuraCap and Humanwell do business, fluctuations in costs, changes to the competitive environment due to consolidation or otherwise, uncertainties as to how Humanwell stockholders may vote on the pending transaction, and the possibility that various closing conditions to the Epic acquisition may not be satisfied or waived (including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the acquisition, or that a material adverse effect occurs with respect to Epic). Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements.

    Sean Weeks
    President
    PuraCap International LLC
    Email
    908-941-5456

    SOURCE PuraCap Pharmaceutical

    Related Links

    Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC





    Tower Pharma Consulting #www.pharma.com

    #pharma consulting

    #

    Welcome to Tower Pharma Consulting

    We are a pharmaceutical consultancy that specialises in pharmaceutical product development and drug delivery. Based in Vienna, Austria, we provide a variety of scientific, technical and project management services to both large and small pharmaceutical/biotech companies and government agencies.

    Services Looking for formulation expertise or seeking an independent evaluation?
    More Info

    The consultancy was founded by
    Dr. Louise Rosenmayr-Templeton,
    a pharmacist with over 18 years’ experience in the fields of pharmaceutical research and development as well as project management.

    The consultancy’s key strengths lie in the following areas:

    • Technology evaluation & benchmarking
    • Development of formulation strategies
    • Formulation expertise & problem-solving
    • Service provider identification & evaluation
    • Management of outsourced projects

    These strengths, coupled with our international experience, enable us to provide tailor-made services for our clients.

    So whether your challenge relates to technology evaluation, development of formulation strategies or finding the right contract service provider, let Tower Pharma Consulting guide you to the solution.

    News Workshop on Successful Early Stage Development of Pharmaceuticals
    More Info





    Home – PPMA Pakistan Pharmaceuticals Manufacturers – Association #big #pharmaceutical #companies

    #pharmaceutical manufacturers

    #

    Central Chairman Message

    Pakistan Pharma Industry is very vibrant and dynamic comprising more than 700 units. It is a knowledge based industry. It s going through a transition phase of modernization to cater local Pharmaceutical requirements and to access more regulated market like Europe and USA.
    Currently Pharma industry in fulfilling more than 95% of the domestic Pharmaceutical requirements. Our goal is ensure availability of quality medicines to all at reasonable price and to enhance exports of the country by accessing more value added markets of Europe and USA.

    Zonal Chairman North Message

    Pharmaceutical industry plays a vital role in the development of a health society and economy. State has a role to guarantee access to health service which can only be ebsured with the help of competitive pharmaceutical industry capable of producing safe, effective and affordable to tackle known disease and new outbreaks.

    ZONAL CHAIRMAN NORTH PPMA

    Zonal Chairman South Message

    It is an honor for me to be elected as Chairman, South Zone (Sindh Balochistan) PPMA. Although it is a very difficult time for survival of Pharma Industry but I am optimistic that with your cooperation and support we shall be able to overcome this difficult time. I have accepted this position with the determination Read Full Message

    MR. HANIF SATTAR

    ZONAL CHAIRMAN SOUTH PPMA





    Humanwell and PuraCap to acquire Epic Pharma for $550m – Pharmaceutical Technology #pharma #executive

    #epic pharma

    #

    Humanwell and PuraCap to acquire Epic Pharma for $550m

    Humanwell Healthcare Group and PuraCap Pharmaceutical have agreed to acquire US-based Epic Pharma in a deal valued at $550m.

    With this investment, Humanwell and PuraCap will expand their presence in the US generics market and existing commercial and manufacturing capabilities.

    The deal includes Epic’s generic product portfolio which includes tablets, two-piece capsules and powder dosage form products, as well as a future product portfolio that will include a series of controlled drug substances.

    Epic’s portfolio consists of 15 marketed generic products and a pipeline of 37 products.

    The acquisition will also bring Epic’s 110,000ft² GMP manufacturing facility in Laurelton, New York, to the companies.

    Humanwell Healthcare chairman Richard Wang said: This acquisition continues to broaden our global investments consistent with our strategy for the creation of a truly global pharmaceutical company for Humanwell Healthcare Group.

    Nearly 215 employees from Epic will join Humanwell and PuraCap’s US operations team.

    The PuraCap US footprint continues to expand our tablet, softgel, two-piece capsules, cream and powder product portfolio.

    PuraCap CEO Dahai Guo said: In addition to strong and growing OTC and branded business units in the US, this acquisition along with our recent acquisition of Blu Pharmaceutical and Blu Carib firmly establishes Humanwell and PuraCap in the US Generic Rx Pharmaceutical segment.

    The PuraCap US footprint continues to expand our tablet, softgel, two-piece capsules, cream and powder product portfolio.

    Subject to certain regulatory and shareholders’ approval, the acquisition is expected to be completed in the second quarter of this year.

    Humanwell Healthcare currently invests, develops and manages healthcare companies.

    PuraCap Pharmaceutical works in the areas of prescription brands and prescription generics, as well as OTC and private label brands.

    Image: The acquisition of Epic Pharma includes a FDA and DEA inspected GMP manufacturing facility. Photo: courtesy of PRNewsFoto / PuraCap Pharmaceutical.

    Related Content





    Pharmaceutical – Healthcare Marketing MBA for Executives #how #big #is #the #pharmaceutical #industry

    #pharma mba

    #

    For more than 20 years, Saint Joseph s University has offered an exclusive industry-focused MBA program designed for working professionals in the pharma, biotech, medical device, diagnostics and healthcare sectors. Students learn to think strategically in the midst of changing health policies and regulations, patent expirations, new product launches, and considerations for payers and patient compliance. Surrounded by accomplished peers, students receive an experiential education focused on maximizing value for all industry stakeholders. This unique environment enables students to bring applicable lessons immediately from classroom to the workplace. Not surprisingly, over the past five years up to 80% of students have been promoted before they even graduate. Through any combination of in-person or online courses, our students discover a tailored and unique academic experience.

    – No GMAT required in lieu of a structured personal interview

    – Start the program any month of the year

    – International residency option

    – Financial Aid Available for U.S. Citizens

    Students are required to complete 24 two-credit courses in various pharmaceutical and healthcare business areas, designed to build from a common foundation toward advanced business principles. How quickly you earn your degree simply depends on how many courses you take per year you may complete your MBA in as little as 12 months, or take as long as six years. For students who already have a master’s degree, we also offer an industry-focused Advanced Graduate Certificate program.





    MBA Programs in Pharmaceuticals: Beyond the Lab #eye #for #pharma

    #pharma mba

    #

    MBA Programs in Pharmaceuticals: Beyond the Lab

    How MBA programs can help students tap into a wide range of roles in both big and small pharma firms

    By all accounts, the pharmaceutical industry is huge, and growing. Recent reports put the worldwide revenue from prescription drug sales as high as almost $1 trillion. And with developing middle classes needing more and more drugs in places like China and India, the industry is globalizing, and is not going to slow down anytime soon.

    Perhaps because of this growth potential, some business students are tuning in. A number of MBA programs that focus specifically in pharmaceuticals have emerged in the past decade, helping students combine business know-how with the technical knowledge that they will need in this scientific field.

    Many students who are interested in these programs find that the industry meshes with their millennial worldview, which tends to be idealistic and strongly entrepreneurial.

    “What I find with this generation is that the healthcare sector in general has become much more popular, because they really like to work in sectors that have products and services that actually have meaning, and can help society,” says Cliff Cramer, who directs Columbia Business School’s Healthcare and Pharmaceutical Management Program, which launched in 2006.

    According to Mahmud Hassan, the director of Rutgers’ Business School’s Pharmaceutical MBA Program, the program is not for everybody, and the students who tend to excel in the program are those who have either an interest in the industry, or a strong technical background (some students might even already have either a PhD or a PharmD.)

    “For the people who have done well, they’ve had science backgrounds or experience in the healthcare industry,” Hassan says, adding that “they may have worked not directly with the pharma industry, but indirectly, like as a consultant, or as a researcher.”

    Due to the way the industry works – products are developed through scientific and technological innovation, and then distributed through a complex supply chain that is governed by evolving regulations – people with some knowledge of the industry, or those who have technical backgrounds, tend to succeed in pharmaceutical-oriented MBA programs.

    Hassan notes that some students also come from other strongly quantitative fields, such as information technology and finance.

    Cliff Cramer says that a previous connection to the industry can spur interest and provide a jumping-in point for a career in pharma. Some people who pursue the Columbia program “have been consulting in the space, and others have broader healthcare experience,” he says, “and some even come from different sectors or different areas, but they bring very strong quantitative and analytical skills.”

    Columbia’s program supplements core business topics with specific insight into both the pharmaceutical sector as well as the healthcare industry more broadly. The specialized curriculum includes a range of courses like “Economics of Healthcare and Pharmaceuticals,” “Investing in Medical Technologies,” and “Strategy and Competition in Pharmaceuticals and Biotechnology.”

    Such programs that offer broader concentrations in healthcare allow students to dive into not only pharmaceuticals, but also the biotech sector, as well as other parts of the rapidly-changing industry. Similar programs include Wharton’s MBA in Health Care Management, which provides some pharmaceutical-specific curriculum, but also addresses the emerging regulatory, legal, and financial challenges of the industry; and Boston University’s Health Sector MBA program.

    And other business schools that have strong pharmaceutical placements might not necessarily offer a specialization in the field, but leverage proximity to large firms in the industry. For example, Copenhagen Business School generally places a fair number of MBA graduates each year in the pharmaceutical industry, without a concentration. Admissions director Thuli Skosana says that this is because the city of Copenhagen sits in what’s known as “Medicon Valley” – Scandinavia’s primary life sciences hub.

    “It’s not the majority of people who come here targeting the pharmaceutical industry, but people certainly find opportunities afterward,” she says, noting that some MBA graduates end up in large pharma companies like Novo Nordisk or in smaller startups that might specialize in bio-medical innovation.

    An array of career options

    Indeed, because the pharmaceutical industry is so large and complex, a huge variety of jobs await well-prepared MBA graduates. In the Rutgers MBA program, students who specialize in pharmaceuticals can also choose a second concentration, usually focusing on a functional area.

    “Supply chain and marketing – those are the most popular combinations,” says Mahmud Hassan, who notes that a good number of other pharma students pursue a finance concentration.

    Graduates of the Rutgers program by and large go into “Big Pharma” firms – giants like Pfizer, Novartis, and GlaxoSmithKline, which, from a revenue standpoint, make up a large percentage of the industry. These companies are so large and sprawling that they can offer jobs for MBA graduates with an array of interests, from roles in research and development and drug delivery management to corporate finance and marketing.

    And often, even those whose goal is to work in a smaller pharmaceutical company or a startup would benefit from getting some experience in a larger company. Because of the way the industry works, “a lot of the financing that the smaller bio-tech companies need is coming from the larger pharma companies,” says Columbia’s Cliff Cramer.

    “If you get some experience with the larger companies, and understand their culture,” he continues, “and then you go to a smaller one, you’re going to be very well-received.”

    Comments





    OWP Pharmaceuticals #ciba #pharmaceuticals

    #world pharma

    #

    The OWP Difference

    The OWP Difference

    The Pharmaceutical Social Enterprise

    How we do this

    When it comes to epilepsy, our goal is to impact pharmaceutical injustice globally, and to promote a future when the best treatment for epilepsy will be available to all people, at all times, in all the world. Solving a problem of this magnitude does not happen overnight. It requires intentional, systematic efforts and the kind of vision that drives our team at OWP Pharmaceuticals. Our vision comes to life through our business model and dedication.

    Founder, Scott Boyer

    Scott Boyer learned early how to fix what’s broken in an industry, and then create something new and thriving. Born in Sioux City, Iowa, Scott was raised by an entrepreneurial dad who took a left-for-dead meat packing plant and turned it into a three-decade success story. Boyer’s Provisions did more than supply quality meat products to the good people of Iowa. It also provided a fifty yard line seat for Scott to

    learn the value of hard work, having a plan, and then working that plan until it was successfully completed. “I did it all,” he says. “Driving trucks, smoking meat, you name it.” Scott worked his college schedule around his duties at Boyer’s Provisions, going to school three days a week and working the other two. He graduated from Morningside College with a double major in Read more

    ROW Impact





    Pharmaceutical industry news, articles, jobs, reports, advice and services #zuellig #pharma

    #pharma marketing

    #

    A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a.

    Slide Deck: Kinetic: A new approach shaping the future of advisory boards How many times have we attended meetings that have little direction, or no clear objectives and left feeling disinterested and disengaged? Our “Kinetic” consulting approach is set to change all.

    Alzheimer’s disease: reviewing the immediate treatment horizon Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer’s disease.

    Anthill awarded full Veeva certification We are proud to announce we have been certified level 4 Veeva multichannel content partner.

    Quick links

    Infographics





    MBA PHARMA MANAGEMENT, Distance Learning MBA program #www.pharma-smart.com

    #pharma mba

    #

    The MBA Program of IIPM focuses on knowledge and skills required by management professionals who plan to work for Indian and multinational corporations. It provides the students with a general management perspective and introduces them to the latest concepts and practices related to functional areas of management. The substantive exposure to Indian and international management practices with a strong case-study orientation is a unique feature of the MBA Program. In addition, the MBA Program is structured in a flexible manner so that working executives can pursue this program without disturbing their careers. IIPM’s Pharmaceutical Marketing MBA is the only industry-specific course designed for Pharmaceutical Professionals. As competition for professional advancement intensifies, understanding the latest techniques in management, innovative marketing strategies and effective methods for corporate growth are a necessity. In an ever-changing business environment, the MBA in Pharmaceutical Management equips you with the knowledge needed to stay ahead of the competition.

    MBA (Pharma Management) is industry-specific program prepares Pharmaceutical Executives with the knowledge and skills required to lead the industry in the 21st century

    Masters Diploma in Business Administration (Pharmaceutical Management)

    Duration 2 Year. Eligibility. Any Degre e

    4 Semester of 6 month each

    Compulsory subjects

    PM 09 Managing Men
    PM 12 Principles of Management
    PM 19 Finance for Managers
    Optional Subject (select any one)
    PM 10 Business Environment
    PM 40 Quantitative Techniques for Managers

    *Award. Diploma in Management

    PM 14 Marketing Management
    PM 18 Managerial Economics
    PM 25 Strategic Management Entrepreneurship
    Optional Subject (select any one)
    PM 49 E-Commerce
    PM 66 ERP MIS

    PM 02 Pharma Distribution Management.

    PM 04 Pharma Product Management.

    PM 61 Brand Management.

    PM 64 Consumer Behaviour.

    Optional Subject (Select Oone)

    PM 05 Paradyme in Pharma Industry.

    PM 17 Marketing Research.

    PM 50 Project Work .

    *Award. PG Diploma in Pharma Management.

    PM 07 Business Communication.
    PM 13 Business Laws.
    PM 33 Project Management.

    Optional Subject (select any one)

    PM 17 Marketing Research.
    PM 24 Corporate Governance and Business Ethics.

    Note. PM 17 may be opted in Sem 3 0r Sem 4





    Jeiven Pharmaceutical Consulting, Inc #azur #pharma

    #pharma consulting

    #

    • TRAINING
      Our school, Pharmaceutical Training Seminars offer a wide array of courses including GMP, GCP, GLP, DEA, QSR, Clinical Supplies, and Regulatory Affairs.
    • CONSULTING
      JPC provides consulting to pharmaceutical, biotechnology, device, and dietary supplement companies.
    • AUDITS GMP/GCP/GLP/GTP/DEA/PAI
      Our team of auditors is available to conduct audits globally. We can audit your site and your contractors.
    • QA/QC
      JPC helps companies stay compliant with FDA regulators through our QA/QC services which include: audits, batch record review, SOPs, CAPA, and training.
    • REGULATORY
      JPC provides expert advice in IND, NDA, ANDA, ANADA, PMA, BLA, 510(k), 505(b)(2) strategy, CMC sections.
    • DEA: CONTROLLED SUBSTANCES
      Our team of former DEA investigators help ensure your company’s compliance to DEA regulations.
    • SOPS
      We author, review and revise SOPs on our client’s behalf. We have many templates which can be used as a starting point.
    • PROJECT MANAGEMENT
      Our project management assistance includes: creating a Clinical Supply Plan from your clinical protocol, creating a timeline in MS Project and estimated budget summary.
    • TECHNOLOGY SERVICES/IVRS
      Our team of computer system and software experts can help your company select, implement and validate IVR vendors.
    • STAFFING
      We can assist your company with temporary, permanent, full-time and part-time employees.
    • VENTURE CAPITAL
      We offer venture capital firms due diligence audits and consulting to assess regulatory compliance.
    • MEDICAL DEVICE
      We provide audits (pre-approval inspections and contractor), and consulting including 510(k) submissions and review for medical devices and, combination products.
    • CSSG
      Our Clinical Supplies Support Group meets several times a year. The goal of our group is to provide a network for clinical supply professionals.
    • SEMINARS
      We offer off-site courses throughout the year on topics such as Clinical Supplies (Basics and Refresher) and DEA.
    • DIETARY SUPPLEMENTS
      We provide 21 CFR Part 111 advice, training and guidance through NutraReg LLC, our sister company.
    • TRAINING
      Our school, Pharmaceutical Training Seminars offer a wide array of courses including GMP, GCP, GLP, DEA, QSR, Clinical Supplies, and Regulatory Affairs.
    • CONSULTING
      JPC provides consulting to pharmaceutical, biotechnology, device, and dietary supplement companies.
    • AUDITS GMP/GCP/GLP/GTP/DEA/PAI
      Our team of auditors is available to conduct audits globally. We can audit your site and your contractors.
    • QA/QC
      JPC helps companies stay compliant with FDA regulators through our QA/QC services which include: audits, batch record review, SOPs, CAPA, and training.
    • REGULATORY
      JPC provides expert advice in IND, NDA, ANDA, ANADA, PMA, BLA, 510(k), 505(b)(2) strategy, CMC sections.
    • DEA: CONTROLLED SUBSTANCES
      Our team of former DEA investigators help ensure your company’s compliance to DEA regulations.
    • SOPS
      We author, review and revise SOPs on our client’s behalf. We have many templates which can be used as a starting point.
    • PROJECT MANAGEMENT
      Our project management assistance includes: creating a Clinical Supply Plan from your clinical protocol, creating a timeline in MS Project and estimated budget summary.
    • TECHNOLOGY SERVICES/IVRS
      Our team of computer system and software experts can help your company select, implement and validate IVR vendors.
    • STAFFING
      We can assist your company with temporary, permanent, full-time and part-time employees.
    • VENTURE CAPITAL
      We offer venture capital firms due diligence audits and consulting to assess regulatory compliance.
    • MEDICAL DEVICE
      We provide audits (pre-approval inspections and contractor), and consulting including 510(k) submissions and review for medical devices and, combination products.
    • CSSG
      Our Clinical Supplies Support Group meets several times a year. The goal of our group is to provide a network for clinical supply professionals.
    • SEMINARS
      We offer off-site courses throughout the year on topics such as Clinical Supplies (Basics and Refresher) and DEA.
    • DIETARY SUPPLEMENTS
      We provide 21 CFR Part 111 advice, training and guidance through NutraReg LLC, our sister company.

    About JPC

    Jeiven Pharmaceutical Consulting, Inc. (JPC) brings over twenty years of experience to the goal of providing pharmaceutical, bio- technology, medical device, and dietary supplement companies with an unparalleled level of service and dedication to ensure the success of their projects.

    Our clients range from the small start-ups to large pharmaceutical firms. They come back to us because they know we will provide them with the highest level of service. The hallmark of our success has been our outstanding customer satisfaction and client retention.

    We take pride in providing, above all else, Reliable Guidance to clients of all sizes.

    Our Expertise

    A note from Marty

    Jeiven Pharmaceutical Consulting, Inc. (JPC) aspires to provide domestic and international pharmaceutical, biotech, and nutraceutical companies with reliable, cost-effective, value-added service, to advance their goals and objectives.

    JPC will fulfill its mission through the application of its unique skills and expert knowledge in the fields of Quality, Regulatory Affairs, Formulations, Process Development, Manufacturing, Packaging and Labeling of Clinical and Commercial Supplies, as well as Staffing and Training.

    Finally, JPC s employees will commit themselves to providing our customers with unparalled customer service and satisfaction.





    Pharma Software for Distribution & Wholesale Billing #government #pricing #pharma

    #pharma software

    #

    Pharma Software

    Software Demo

    • Multi Rate, Price List, & Discount
    • Cash / Credit / Split Invoice & Challan
    • Sales Return & Replacement on Sale Bill
    • Party Wise Rate, Discount and Scheme
    • Salesman / Route / Area Wise Bills & Reports
    • Indication for Loss, Min, Max, New / Old Rate & Expiry
    • Negative Stock Billing Facility
    • Self-Designed Price List (Set Formula in Price List)
    • Sales Return on Same / Separate Bill & Its Adjustment
    • Back Date Stock Position at the Time of Billing
    • Switch Over from Bill to Bill Anywhere
    • Godown Wise Billing & Stock Position
    • Bill Import / Export & Message on Bill
    • Auto Calculation of Levies & no Chance of Manual Mistake
    • Display last four Deals at the Time of Billing
    • View O/s Stock, Ledger. Last Deal of Sale & Purchase Returns, Receipt Payment Bill Modification at the Time of Billing
    • Counter Sale Entry Provision
    • Party History Dashboard on Party Selection
    • Provision to Load Item from Other Bill
    • Display Last 4 Deals at the Time of Purchase to Cross Check Rate Deal, Disc Tax & Cost
    • Purchase Planning & Purchase Order Management
    • Supplier Wise Various Outstanding Reports & Remainder
    • Pending DR / CR & Replacement Notes
    • Auto Barcode / Label Printing from Purchase Bill
    • Fix Sales Rates & Deals at the Time of Purchase
    • Online Shortage Management
    • Purchase Costing Comparison
    • 1000’s of Purchase Reports & Analysis
    • Online / Softcopy Purchase
    • Items Wise Double Percentages Discounts
    • Item Wise Double Volume Discounts
    • Four Different Discounts on Complete Bill
    • Party Wise Discounts & Schemes Pre-Fixing
    • Data Wise Schemes, Quantity Based Rate & Discounts
    • Various types of Schemes, Like A Item Free with B Item Etc.
    • Accounts Vouchers & Cheque Printing
    • Receipt/ Payment Advice
    • Sales / Purchase Invoice, Estimate A7 Challan
    • Sale / Purchase Return Replacement & Price Difference
    • Debit Note/ Credit Note
    • Sales Orders / Purchase Order
    • Bank Pay in Slip & TDS Certificate
    • Stock Transfer Memo
    • Delivery Note, Goods Receipt Note & Dispatch Summary

    Fully User-Configurable Invoicing

    • Vat Invoicing Tax (Tax / Retail)
    • Tax Inclusive, Exclusive & MRP Billing
    • Multiple –taxes in Single Invoice
    • Manufacturing / Trading Excise Invoice
    • Export Invoice & Packaging Slip
    • Option for Pre-printed Stationary
    • Self-Designable Invoice Format

    Taxation Reports / Registers

    • Sales Tax / Purchase Tax Summary
    • Sales Tax Account Registers & Vat Returns
    • Sales Tax Forms Receivable / Issuable & Reminders
    • Service Tax, F.B.T. T.D.S, T.C.S Excise, Cess & H.E. Cess
    • Party Wise Vat Summaries
    • Check List
    • Cash Flow, Funds Flow & Ratio Analysis
    • Budgets / Targets / Credit Limits
    • Online Graph, SMS & E-mail
    • Any Report Export to Word & Excel
    • Sales / Purchase Analysis
    • Gross Profit Analysis
    • Financial, Expenses & Budget Analysis
    • Operator Wise Powers & Boundations with Operator Log Book
    • Smart Vat Patch no Need to Update software
    • User–Definable Warning Alarms & Colorful Indication
    • Year-Wise Data Backup and Restore
    • Data Export to Word / Excel / Text File
    • Draft Mode & GUI Printing
    • Last Year Comparison with Various Reports
    • Bird’s Eye View of Accounts
    • Powerful Query System
    • Credit Limit in Amount, Bill & Days with Stop Billing Facility
    • User Definable Hot Keys
    • Data Security with Self Backup & Carbon Copy system
    • Sales/Purchase, Bank, Ledger & Data Freezing on any Date
    • Auto recovery of Bill for unsaved bill due to Power Off
    • Attached with Hospital software & work on their guidelines
    • Any Report Printing from anywhere
    • Single User & Multi User
    • 100% Data Security & Accuracy
    • Tried & Tested (100% Error Free)
    • Multi-Currency, Unit, Godown & Financial Years Facility
    • Calculator & Cash Return Adviser
    • Month Calendar with Appointment Dairy & Note Pad
    • Supplier, Customers & Personal Directory
    • Telephone Book Envelope & Labels Printing
    • Hot Keys for Switch Over from one Report to Another
    • software / Operator/ Company Password & Boundations
    • Data Security with Self Backup & Carbon Copy System
    • Sale / Purchase, Bank Ledger & Data Freezing on any Date
    • Any Report Printing from Anywhere

    Comprehensive Financial Accounting

    • All Book of Accounts & Final Results
    • Balance Sheet with Various Schedules
    • Configurable Sales & Purchase Registers
    • Outstanding Reports and Analysis
    • Configurable Payment Reminder Letters
    • Configurable Statement of A/c
    • Interest Calculation & Bank Re-conciliation
    • Depreciation Chart (as per Co. Act / it Act)
    • Cost Centers with Grouping
    • Funds Planning / Bank Planning
    • Post Dated Cheques Facility
    • Voucher Approval System
    • All Books of Inventory
    • Brand, Group & Category Wise Inventory
    • Stock Valuation on Multiple Methods
    • Item Wise Gross Profit
    • Primary and Alternative Unit for Each Item
    • Party-wise Price Structure for Items / Groups
    • Multiple Prices Lists of Items
    • Sales & Purchase Order Processing
    • Batch / MRP / Size / Shade / Reference / Serial No. Wise Inventory

    Business Boosters

    Attraction About Marg

    Relative Products

    What is the need for computerization?

    In today’s scenario with the increasing inventory it is very difficult to keep a count of all stocks and accounts. It is also difficult to remember debtors and creditors and its outstanding’s. Computerization is the only way to keep a track of inventory and accounting.

    Will this help in stopping pilferage’s?

    When the staff comes to know that the store is computerized and the owner has all the knowledge of stocks and cash, the chances of pilferage’s reduces drastically.The best example is when in a store sign board of “You are under CC TV surveillance” is mentioned then there are very few chances of people doing any mischief’s. There is a general thought in owners mind that almost 3-4% stocks are pilfer aged, with the help of computerization this 3-4% can be saved.

    Will computerization help increase my SALES?

    Yes surely, with the help of computerization speed of billing increases by many folds and the customer now-a-days has more faith in computerized bill as the general thought is that if the bill is computerized then the rates and the products they are buying are genuine.

    Why only MARG for my business?

    MARG is an ISO 9001-2008 certified India’s one of the most leading integrated software companies with trade specific software solution for Retailers, Distributors, Manufacturers, Supply Chain, Retail Chain & Erp.

    Marg has 1500 setups to customize the software it according to your requirements.We have 6 Lacks plus satisfied customers with the help of our highly skilled global workforce consisting of 150 employees in head office and more than 1,500 service station employees in 586 cities of India with 370 exclusive support centers.

    Customer Review

    Our Clients

    Articles





    Indian Pharmaceuticals Industry Analysis #pharmaceutical #news

    #pharmaceutical industry research

    #

    Indian Pharmaceuticals Industry Analysis

    Increasing investments in the sector

    The Indian pharmaceuticals market increased at a CAGR of 17.46 per cent in 2015 from US$ 6 billion in 2005 and is expected to expand at a CAGR of 15.92 per cent to US$ 55 billion by 2020.

    By 2020, India is likely to be among the top three pharmaceutical markets by incremental growth and sixth largest market globally in absolute size.

    India s cost of production is significantly lower than that of the US and almost half of that of Europe. It gives a competitive edge to India over others.

    Generic drugs form the largest segment

    With 70 per cent of market share (in terms of revenues), generic drugs form the largest segment of the Indian pharmaceutical sector.

    India supply 20 per cent of global generic medicines market exports in terms of volume, making the country the largest provider of generic medicines globally and expected to expand even further in coming years

    Over the Counter (OTC) medicines and patented drugs constitute 21 per cent and 9 per cent, respectively, of total market revenues of US$ 20 billion

    Last Updated: January, 2016

    Indian pharmaceutical sector accounts for about 2.4 per cent of the global pharmaceutical industry in value terms and 10 per cent in volume terms and is expected to expand at a Compound Annual Growth Rate (CAGR) of 15.92 per cent to US$ 55 billion by 2020 from US$ 20 billion in 2015.

    With 71 per cent market share, generic drugs form the largest segment of the Indian pharmaceutical sector. By 2016, India is expected to be the third-largest global generic Active Pharmaceutical Ingredient (API) merchant market. The country accounts for the second largest number of Abbreviated New Drug Applications (ANDAs) and is the world s leader in Drug Master Files (DMFs) applications with the US.

    Indian drugs are exported to more than 200 countries in the world, with the US as the key market. Generic drugs account for 20 per cent of global exports in terms of volume, making the country the largest provider of generic medicines globally and expected to expand even further in coming years. Pharmaceuticals Exports Promotion Council (Pharmexcil) expects pharmaceutical exports to reach US$ 25 billion in 2015.

    The Government of India plans to set up a US$ 640 million venture capital fund to boost drug discovery and strengthen pharmaceutical infrastructure. The Pharma Vision 2020 by the government s Department of Pharmaceuticals aims to make India a major hub for end-to-end drug discovery.

    Sectoral Presentation (January, 2016)

    Industry

    Related NewsMore

    Last Updated: September 02, 2016

    • Kiran Mazumdar-Shaw conferred knighthood by French government
    • PPP model can make India one of top 5 global pharma innovation hubs: Study
    • Lupin to file its first biosimilar etanercept for approval in Japan in 2017
    • Rubicon Research in talks to raise Rs240 crore from Everstone Capital, HNIs
    • Breakthrough cancer drugs all set for India launch

    The generics market is expected to grow to US$ 26.1 billion by 2016 from US$ 11.3 billion in 2011.

    Pharmaceuticals India

    Pharma Clusters

    Industry Contacts

    Posters

    WINNING THE WORLD

    Indian pharma company have won around 40 per cent of all Abbreviated New Drug Approval (ANDA) from the US Food and Drug Administration (FDA) between j.

    IBEF Publications

    India Now Magazine

    India Now Business and Economy

    Powered by the Who’s Who of India

    India: Unlocking our skies

    Dr. Shobhit Jain, IRS, Deputy CEO IBEF

    In a major boost to regional air connectivity, the Government of India has recently announced that it plans to set up 50 new airports in the country over the next three y.

    GST: Great Step of Transformation

    Ravi Capoor, IAS, Chief Executive Officer, IBEF

    The much-awaited Constitution Amendment Bill for Goods and Services Tax (GST) was passed in the Parliament recently and is expected to be implemented by April 2017 replac.

    Making SMEs bankable and banking on SMEs

    Mr. R. Narayan, Founder & CEO, Power2SME

    India is considered a bright spot in the gloomy, global economic scenario today. The country with a GDP growth of 7.6% (in 2015-16) has topped the World Bank’.

    Brand India Engineering at INNOPROM 2016

    Ravi Capoor, IAS, Chief Executive Officer, IBEF

    India successfully showcased its strengths in the field of engineering at the flagship Russian international trade fair, INNOPROM 2016 held at Yekaterinburg, Russia from.

    How is OYO catering to the changing needs of Millennials

    Ritesh Agarwal, ‎Founder & CEO, OYO Rooms

    As we see one of the largest generation in the history move into the earning and then spending stage in their lives, it is imperative that marketers understand the behavi.

    India: The most open economy for FDI

    Ravi Capoor, IAS, Chief Executive Officer, IBEF

    The Government of India has recently announced radical liberalisation of the Foreign Direct Investment (FDI) regime by easing norms for a host of important sectors includ.

    ideas More

    A Big Step Forward
    Krispian Lawrence co-founded Ducere Technologies with Anirudh Sharma in 2011. Lechal is the outcome of their concerted efforts to use haptics in the wearable technology space. Both Anirudh and I were always fascinated by wearable technology, and were tinkering with various ideas in this space. But the concept was nascent.

    JOIN IBEF.org





    Global Pharma Companies #ajanta #pharma #kamagra

    #world pharma

    #

    Global Pharma Companies

    At Covance, we have helped the pharmaceutical industry develop more medicines worldwide than any other company, including the top 50 best-selling drugs on the market. Leveraging this experience, we go beyond traditional service delivery, providing solutions that unlock opportunities for your development programs and deliver results that matter. Partner with us and see why more than 90% of the top 20 global pharmaceutical companies are repeat customers.

    Solutions for transforming results.

    Every client’s needs are unique when considering a drug development partnership. That’s why we offer a variety of solutions that align with a strategy that works best for you.

    Navigating complexities in drug development:

    Lead Optimization : Accelerate your candidate selection with integrated safety and efficacy solutions.

    Biologics : Expedite your biologics development with help from our dedicated biologics molecule management team.

    Xcellerate ® Clinical Trial Optimization ® . Optimize your clinical trial enrollment with our data-driven drug development approach.

    Xcellerate ® Monitoring . Identify, prevent and effectively manage risks to yield the greatest return.

    Expanded Laboratory Management Solutions: Manage risk and uncertainties to help ensure supplier quality.

    Maximizing ROI on your investment:

    • Complete PoC™ . Maximize asset value, combining perspectives in safety, efficacy, quality and commercial potential to quickly reach decision points.
    • Functional Service Provider . Access professional clinical support through our flexible staffing services to maximize your resources and optimize your cost.
    • Companion Diagnostics (CDx) : Realize development efficiencies through co-development of the diagnostic with the therapeutic.
    • Covance MarketPlace . Gain better line of sight to viable candidates with Covance’s innovative solution connecting companies that are interested in licensing, selling or purchasing molecules.

    Strategic partnering to gain efficiencies.

    Driving R D productivity and accelerating drug development timelines is critical. Our scalable and streamlined development model paired with a flexible fixed-cost infrastructure is designed to deliver global pharma solutions. As your strategic partner, we are continually improving collaboration, providing experience-based insights and ultimately leading you to greater innovation.

    Alliance Management.





    A – Z Pharmaceutical, Inc #ajanta #pharma #products

    #drug manufacturer

    #

    A Z Pharmaceutical, Inc.

    Latest Drug Information Updates

    • Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent.
    • Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated.
    • Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the.
    • Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A.
    • Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB).
    • Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing.

    More.

    Was this page helpful?

    Drugs.com Mobile Apps

    The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

    Support

    About

    Terms Privacy

    Connect

    Subscribe to receive email notifications whenever new articles are published.

    Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated Aug 9th, 2016), Cerner Multum (updated Aug 1st, 2016), Wolters Kluwer (updated Aug 8th, 2016) and others. To view content sources and attributions, please refer to our editorial policy .

    We comply with the HONcode standard for trustworthy health information – verify here

    Copyright 2000-2016 Drugs.com. All rights reserved.





    WORLD PHARMA LICENSING CONGRESS #core #pharma

    #world pharma

    #

    WORLD PHARMA LICENSING CONGRESS

    World Pharma Licensing Congress 2015 is an exclusive private meeting that will bring together leading pharma licensing and business development executives, academia and industry associations to address the key industry challenges and the future of Pharma Industry at the London Stock Exchange.

    Pharma and Biotech companies are in need of alternative methods and strategies to strengthen and fuel their IP portfolios whilst reducing costs, shortening timescale and maintaining quality and high returns on investment. The WPLC 2015 is designed to act as a platform for developing innovative strategies for the stimulation of industry growth.

    Topics to be discussed include:

    • Creating robust and sustainable patent pipeline through M A and Licensing
    • The main considerations for a successful market entry strategy
    • Competitive Differentiation in Emerging Markets: Minimising potential risks and enhancing profts
    • Identifying trends and drivers in pharmaceutical innovation and deal-making
    • The global threat of parallel importation and counterfeiting in the pharmaceutical industry
    • Open innovation and collaborative partnerships: Safeguarding your IP portfolio

    WPLC 2014 breakdown of attendees by industry:





    Current Issue #pharmaceutical #advertising

    #pharmaceutical manufacturing

    #

    Pharma Manufacturing

    June 2016 Issue

    Free Subscriptions

    Most Popular

    Novartis’ Alcon Penalized $16M for Illegal Exports to Iran

    2016 Contract Pharma Trends Ebook

    FDA OK’s Novartis Biosimilar to Amgen Arthritis Drug, Enbrel

    Valeant Sued for Alleged Racketeering, Linked to Philidor

    Novo Nordisk CEO Steps Down

    2016 Contract Pharma Trends Ebook

    Mylan Under Fire for Huge Price Hikes on More than Just Its EpiPen

    Work for this Biotech Startup, Get a Free Tesla Car

    FDA Warns China API Maker for Hiding Quality Testing Data

    Innovation in Quality Metrics

    Janssen’s Historic FDA Approval

    2016 Contract Pharma Trends Ebook

    Pfizer Might Have Takers for Struggling Hospira

    On Solid Ground: Pharma’s Most Mature Dosage Form Endures

    On the Cusp of Change

    Weighing and Dispensing: Do it Right

    Annual Product Reviews: How to Conduct an Effective Annual Product Quality Review

    CAPA and Root Cause Analysis

    USP Updates and for Microbial Testing of Non-Steriles

    Reporting Failures and Process Deviations: A Closed-Loop Approach

    Pharma Manufacturing

    About

    Content

    Magazine

    Site Tools

    Stay Connected





    Pharma leaves ad agencies behind for in-house digital marketing teams #hra #pharma

    #pharma ad agencies

    #

    Pharma leaves ad agencies behind for in-house digital marketing teams

    Brands are ditching agencies and bringing digital marketing in-house in bigger numbers than ever, and that includes pharma companies. A new study from the Society of Digital Agencies found that “the percentage of clients taking full responsibility for digital efforts at their companies grew significantly” year over year.

    In fact, 27% of marketers surveyed don’t work with outside agencies for digital marketing, up from just 13% in 2014. More than one-fourth (28%) said they now do all digital marketing in-house, with an overall one in seven planning to decrease marketing spending with digital agencies this year.

    But the study didn’t ask why, so Mark Schaefer, a college educator, marketing consultant and author, decided to ask companies, including several pharmas, what’s going on for an online article in the Harvard Business Review .

    He found that drugmakers are like their counterparts in many industries, when it comes to their regard for advertising agencies.

    “It’s a matter of value, customer responsiveness, and a general inability of agencies to break through decades of organizational history to respond to fast-changing needs,” he said in an email interview. “Another factor is the desire by companies to own the valuable data and the more intimate customer relationships created in a digital space compared to traditional channels.”

    Pharma does differ in other ways from consumer marketers. Increasing use of social media, which is helping to drive the shift away from agencies, is lagging in pharma compared with consumer brands. But Schaefer said that’s changing. Pharma companies are giving up waiting for FDA guidance, or they should at least be thinking about it.

    “By far the biggest reason pharma is generally behind on social is due to regulatory concerns. However, this is starting to change,” he said. “Companies are recognizing that for many people, social channels are a primary source of information and they are finding ways to connect in small but important ways.

    “I don’t think there is any doubt that this rate of change simply must accelerate. The FDA has not been too helpful in this space, so the companies have to figure this out on their own and apply the resources necessary to join the rest of the world. I believe the companies that step out and establish a competency in this space will flourish, especially now when brand-building and trust is so important for business success.”

    Another area where pharma tends to trail consumer marketers is in the B2B trend of social selling, in this case to physicians and healthcare practices. Schaefer said that he’s seen more action in training for pharma companies in that area recently, which he called a good sign in “an area ripe for opportunity.”

    Special Reports: The top 10 pharma companies in social media | The top 10 advertisers in Big Pharma

    Related Stories:
    Pharma ad budgets to dip in 2016, but J J, Pfizer, Roche and Novartis should still top $2B
    Pharma’s ad spend vaults to $4.5B, with big spender Pfizer leading the way
    Some ad types are calling it: ‘Pharmageddon’ is over. DTC is back.
    In latest marketing-reform move, GSK recruits in-house doctors to speak for products





    Top 25 Pharma Companies in Japan – Top Pharma List #orchid #pharma

    #pharma company

    #

    Top 25 pharma companies in Japan

    Note: The 2013 ranking uses 2013 exchange rates for both its 2013 and 2012 values, to remove the effect of currency fluctuations. The 2012 ranking similarly uses 2012 exchange rates.

    Data by GlobalData

    GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

    To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

    Featured jobs

    Principal Medical Writer Great salary and benefits
    ID Search Selection

    Director, Scientific Services Great salary and benefits
    ID Search Selection

    Director, Scientific Services 80 – 100,000 or more according to skills and experience + benefits
    Media Contacts (Recruitment Consu.

    Subscribe to our email news alerts

    Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities.

    Slide Deck: Kinetic: A new approach shaping the future of advisory boards How many times have we attended meetings that have little direction, or no clear objectives and left feeling disinterested and disengaged? Our “Kinetic” consulting approach is set to change all.

    Alzheimer’s disease: reviewing the immediate treatment horizon Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer’s disease.

    Anthill awarded full Veeva certification We are proud to announce we have been certified level 4 Veeva multichannel content partner.

    Quick links

    Infographics





    CRM Solutions for the Pharmaceutical Industry #pharma #validation

    #crm for pharma

    #

    Time is of the essence in the pharmaceutical industry, thanks to the lengthy lead time for new medications and the slim window of patent exclusivity, so you can t waste a moment to a poorly informed sales team or a misplaced contact file. Fortunately, there is a solution: many pharmaceutical firms are turning to customer relationship management software to guide their sales teams and grow their revenues. CRM software can centralize your contacts and leads, help you organize your staff s work for maximum productivity, and even inventory your samples and help monitor your spending outlays to ensure regulatory compliance.

    This resource will help you learn how to choose the best CRM for your pharmaceutical business. You will learn what particular qualities are needed in pharmaceutical CRM, as well as what qualities you will need to keep in mind when deciding what platform best meets your needs.

    Why does the Pharmaceutical Industry have Different CRM Needs?

    Promotional and R D budgets keep rising, and new regulations make many of the techniques used by pharmaceutical reps more difficult or impossible to use without technological support. Large companies and individual representatives alike need to build long term relationships with care providers to drive new sales, and must do so quickly, before the special advantages given to new patents on medications expire. New laws present new challenges, restraining representatives and increasing the workload of primary care physicians, making it all the harder to get in touch with them.

    Historically, the relationship between sales representatives and physicians has been one of relatively slow–paced and friendly discussion, with off–site trips and lunch and dinner meetings being typical. The combination of new regulations and the increased workload of physicians makes these easygoing relationships harder to cultivate. One study from IDC Health Insights suggests that the average primary care physician will go from treating 1,500 patients to treating 8,000. That same study indicates that the window of contact sales representatives have with physicians may be as little as thirty seconds.

    CRM for the Pharmaceutical Industry Prophet CRM by Avidian

    A CRM for the Pharmaceutical Industry (that runs inside Outlook).

    What Customer Relationship Functionalities are Important to Pharmaceutical Companies?

    Pharmaceutical CRM software can help your team meet these challenges. Whether through specialist pharmaceutical CRM or a more general system, you can drastically increase efficiency through client contact tracking, mobile device support, and cloud–based databases. By carefully tracking client contacts, you can avoid wasting your sales team s time, as well as avoid violating regulations. The preferences of your various contacts can also be collected in this manner, making communications smoother. Customized marketing approaches can be developed and deployed in minutes from a CRM–supported database. Many pharmaceutical CRM software solutions include tracking for sample products as well as regulatory compliance systems, and the best pharmaceutical CRM solutions offer thorough mobile device support, helping representatives on the road.

    Customer relationship management software for pharmaceutical companies can also support sales teams more directly. The best CRM for pharmaceutical companies offer cloud–based databases, giving personnel access to all the information they need. When coupled with mobile integration, this helps representatives on mobile devices provide real–time information on sales to the home office immediately.

    3 Ways to Know You re Ready for a CRM Solution

    Before purchasing a pharmaceutical CRM software solution, you should consider these questions.

    1. How do you track your clients and leads? Many sales systems are informal and rely on personal networks of trust and contacts. Leads can often be hard to find and even harder to leverage toward profits. CRM software can help you combine disparate contact networks into a single unified database, avoiding wastes of time and money. CRM lets you make the best use of that tiny window of access in a customer s busy day.

    Are you complying with regulations? Compliance can present major challenges, but most implementations of CRM for pharmaceutical industry clients can make it a breeze. You can easily track client contracts and sales, making sure that your representatives don t inadvertently break spending limits or other limitations on their sales work. Other factors, such as sample medications, can also be tracked with CRM.

    Is your staff technology–friendly? Any new system can cause problems, and many CRM solutions create issues for your IT staff. Not only does this put pressure on those employees and your bottom line, it can lose you sales when systems go down. Recent pharmaceutical CRM solutions feature remote support and options for a cloud–based system which can take the burdens of server maintenance off of your team.

    How Prophet Can Help Pharmaceutical Reps Succeed

    Prophet provides a scalable, easy–to–implement CRM system that can be easily tailored to meet the scale of your company, no matter how big or small. Prophet smoothly integrates with Microsoft Outlook, making it easy for your sales team to keep using the system. Your current contacts and leads can be integrated quickly, sometimes in less than an hour, letting you get to work. You can prepare reports and structure automatic client–contacting routines through email or regular notices to your staff as well.

    That s just where Prophet begins. Prophet provides workflow and contact management advantages, as well as comprehensive support and specialized training. You can provide system access in an unlimited number of divisions and departments, putting contacts and leads to use nationwide or worldwide. Custom records solutions for sample tracking and compliance can help you succeed.

    Praise for Prophet CRM from Industry Professionals

    We had been using an internal CRM program for years, but with the Physician Payment Sunshine Act, we just couldn t keep up, and our new sales plummeted 30% over two quarters. We were already using Outlook in the office, so Prophet was a great fit; we ve made up our lost ground and we re seeing 3% more quarterly sales growth than we did before. Love it! Elizabeth Grimaldi, Sales Director, Autumn Health Management Solutions

    Our company provides niche products and we make many of our sales contacts through direct physician contacts. Our sales team was communicating poorly, missing some physicians for months and bothering others often enough that I got angry phone calls. At an industry conference I heard about pharmaceutical CRM software and took the plunge the Monday afterwards. Now my sales reps can check their information on the road, and make sure we make the contacts we need. It was fast, inexpensive, and our net profits broke $5 million this year. I m already thinking of expanding so we can get a custom sample–tracking solution. Brian Vandergrif, CEO, BeneMaga Pharmaceuticals





    Top 100 Agencies 2014: PulseCX – Medical Marketing and Media #bayer #schering #pharma

    #pharma ad agencies

    #

    Top 100 Agencies 2014: PulseCX

    A new name illustrates this agency s new strategy and focus

    Download: PulseCX

    PulseCX has been through quite a few changes over the course of the past year—the most obvious of those changes being the agency’s name. The Montgomeryville, PA firm, formerly known as Roska Healthcare Advertising, took on its new name this past May 1. And while the people and the client roster at the agency may remain the same, its leaders say that the new name will help connect the brand to what has become its major focus: the customer experience.

    “Over the last 12 months or so we’ve been working on a new brand,” says agency CEO Jay Bolling. “PulseCX (the CX stands for ‘customer experience’) is really a reflection of the work we’ve been doing over the last year and a half, two years or so. It really captures a lot of our heritage in direct and relationship marketing, looking to deliver the brand through the customer experience. We’ve put together a process that explores the customer experience, and not just to mine the insights but really to look at where those moments of truth are where we can assert the brand into that experience and tell a story to which our patients and healthcare professionals can relate.”

    The name change, though, is hardly the agency’s only piece of big news; the past year was filled with plenty of more substantive achievements. In 2013 the former Roska grew revenue by more than 20% while winning a stack of new business, including four brands in the Actavis women’s healthcare portfolio; another three brands from Emergent BioSolutions; agency of record status for Silvergate Pharmaceuticals’ Epaned, a powder formulation of the ACE inhibitor enalapril; and social media strategy work for Amgen’s bone cancer med Xgeva. The agency also added a number of new senior staff members, including executive VP chief creative officer Tina Fascetti, VP client services Ken DePinto, VP marketing operations Rob DiDio, and VP finance Marc Loeb.

    The social media opportunity with Amgen is a particularly exciting one for the PulseCX team. “This was the first time (Amgen has) ever engaged a partner to be a social media strategy hub, and we were honored to do it,” says agency president David Zaritsky.

    “With the FDA regulations loosening up, they engaged us to create a roadmap of how they would connect with physicians and patients from a social media standpoint,” he added. “They’re really building some immersible experiences in the social media space. We’re incredibly excited not only to work with Amgen because it’s Amgen, but because this, we feel, is going to be a benchmark relationship for the rest of the industry.”

    PulseCX is also finding itself doing more comprehensive AOR work for both patient and physician audiences on the same brand, most notably in its relationship with Emergent BioSolutions to support the hemophilia B community. According to Bolling, this sort of “both sides of the fence” approach is beginning to catch on in the industry after the pendulum moved a bit too far in the other direction.

    “We as an industry should really de-silo our target audiences, especially around professionals and consumer,” he says. “They’re often looked at by different teams and different sets of strategies and approaches. But we’re starting to work with them on both sides so that we can affect that dialog and bring them together. If we’re changing behavior, it’s got to come from both sides. It cannot be just one way facing each other.”





    Pharmaceutical Executive Home #vertex #pharma

    #pharmaceutical representative

    #

    Featured E-Books

    Strategic management of the supply chain is vital to winning with customers. Cost and quality are important, but they are not the only things customers care about: New services, flexibility in relationships, supply reliability, and creatively overcoming obstacles in delivery of products are also core values. Pharmaceutical product portfolios and customers are becoming more complex. To stay ahead, customer-focused supply-chain capabilities is becoming an increasingly crucial part of a company s competitive advantage. Visit the resource center.

    The Changing Contours of Drug Commercialization, a new e-book from the editors of Pharmaceutical Executive. sheds light on solutions and strategies uniquely within a manufacturer s own sphere of control that can help navigate the often unforgiving transition from registration to the real-world battle for clinical acceptance and market share. Visit the resource center.

    The industry s much talked-about patient-centered approach requires more than lip-service and organizational redesigns. In order for the patient to emerge center stage in a commercial approach, it s necessary for manufacturers to shift prioritization s to help the greatest number of patients gain access and remain on treatments.

    Success in today s rapidly changing market access world depends on understanding your product s value through the eyes of payers and shaping crucial value communication around the needs of market access stakeholders as much as it does on developing solid evidence of the value of your product.





    Novartis – sales performance, data and rankings – Top Pharma List #sami #pharma

    #pharma company

    #

    Novartis

    Data by GlobalData

    GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

    To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

    Featured jobs

    Director, Scientific Services Great salary and benefits
    ID Search Selection

    Principal Medical Writer Great salary and benefits
    ID Search Selection

    Director, Scientific Services 80 – 100,000 or more according to skills and experience + benefits
    Media Contacts (Recruitment Consu.

    At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human.

    Slide Deck: Kinetic: A new approach shaping the future of advisory boards How many times have we attended meetings that have little direction, or no clear objectives and left feeling disinterested and disengaged? Our “Kinetic” consulting approach is set to change all.

    Alzheimer’s disease: reviewing the immediate treatment horizon Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer’s disease.

    Anthill awarded full Veeva certification We are proud to announce we have been certified level 4 Veeva multichannel content partner.

    Quick links

    Infographics





    Dragon Pharma Steroids #mcneil #pharma

    #dragon pharma

    #

    Dragon Pharma Steroids

    Dragon Pharma Europe

    Xenometrix, Inc. has granted a worldwide license for gene expression profiling to Genometrix Incorporated, giving Genometrix access to claims covered in issued U.S. and European patents. The license is non-exclusive and covers the collection of gene expression profiles utilizing all platforms including microarrays. Genometrix is a pioneer in chip-based platforms and is positioned well to[ ]

    Techniclone Corporation was issued U.S. Patent No. 6,036,955 on March 14, 2000 entitled Kits and Methods for the Specific Coagulation of Vasculature by the U.S. Patent and Trademark Office. This patent covers particular methods of inducing molecules on tumour blood vessels for subsequent targeting and destruction and is a valuable addition to Techniclone s existing broad[ ]

    Crescendo Pharmaceuticals Corporation has announced that ALZA Corporation has exercised its option to obtain a worldwide license to DUROS leuprolide (Viadur), a once-yearly implant for the palliative treatment of advanced prostate cancer. DUROS leuprolide is the first product to provide continuous, 12-month testosterone suppression with a single treatment. Under the terms of its license agreement[ ]

    Cellegy Pharmaceuticals, Inc. has initiated a second Phase III clinical trial to provide confirmatory evidence that Anogesic (nitroglycerin ointment) reduces the average daily pain associated with anal fissures. Initiation of this trial follows review by the US FDA of the study protocol and the results of a recently completed Phase III trial. In the recently[ ]

    EntreMed, Inc. announced that U.S. Patent No. 6,025,688 has been issued covering all antiangiogenic fragments and methods of production for its potent angiogenesis inhibitor, angiostatin protein. The patent also covers antiangiogenic fragments of angiostatin protein that may contain amino acid additions, deletions, or substitutions, which means that any products developed through alterations to the parent[ ]

    DoubleTwist, Inc. has announced that Berlex Laboratories, Inc. has licensed DoubleTwist s proprietary Clustering and Alignment Tools. As DoubleTwist s best-selling product, the computational tools enable companies to quickly cluster and align high volumes of expressed sequence tags (ESTs) and genomic sequences into full-length gene sequences suitable for gene indexing and other applications in drug discovery. We[ ]

    Biacore International AB has entered into a collaborative agreement with SmithKline Beecham Pharmaceuticals, whereby the pharmaceutical giant will evaluate Biacore s new prototype high performance system in preclinical and ADME drug screening studies.The collaboration marks yet another milestone in Biacore s commitment to providing novel analytical systems to help the pharmaceutical industry increase the flow of high-quality[ ]

    ValiGene and Kimeragen announced today that they will merge to create ValiGen, a EuroAmerican functional genomics company. The newly formed ValiGen will combine the genomics platform under development at Valigene with chimeraplasty, the unique gene correction technology being developed at Kimeragen. The new company will pursue commercial opportunities for its technologies in three areas: ValiGen[ ]

    Genome Therapeutics Corp. and ICAgen, Inc. have announced an agreement that utilizes Genome Therapeutics technology to facilitate the assessment and development of a clinical trial design protocol for one of ICAgen s ion channel targets. The genomics technology utilizes polymorphism analysis in subgroups of the target patient population to rapidly determine the target s efficacy and thus[ ]

    CytoGenix Inc. has executed the first license for the use of its proprietary single stranded DNA intracellular expression vector (TroVec) to PharmaGenix LLC. owned jointly by CYGX and PCCA (Professional Compounding Centers of America Inc). PharmaGenix is the first company to combine the traditional science and skills of compounding pharmacists with those molecular biologists and[ ]





    Digital CRM for Pharma Companies #www.buy-pharma.com

    #crm for pharma

    #

    Pharmaceutical

    Maximize Prescriptions

    • Consolidate physicians’ profiles into a central repository to understand their sphere of influence.
    • Determine physicians’ product awareness, varying drug perceptions, prescription habits (Rx/ NRx/ TRx) and recent preference shifts.
    • Plan and monitor activities of medical representatives on daily basis.
    • Pinpoint and record decision makers at hospitals and nursing homes.
    • Analyze feedback for competitors products and services to develop product strategies.

    Key Opinion Leader Management

    • Segment the KOLs on various parameters like influencing capabilities, soft skills, publications, etc.
    • Develop relationship strategies and activities on basis of these parameters.
    • Objectively measure quality of relationship with each KOL.
    • Enjoy significant savings with improved regulatory compliance.
    • Market new drugs with a reduced time frame.
    • Record feedback in a systematic manner and plan future activities.

    Strengthen Delivery Network

    • Create a comprehensive view by profiling chemists, their consumption patterns and in-store competition activities.
    • Understand chemists purchase patterns, stock cycle and supply lines for accurate demand forecasting.
    • Engage with chemists and stockists to understand key influencers in their catchments.
    • Devise collaborative promotions to introduce new products, build brand loyalty and strengthen relationships with stake holders.

    Empower Workforce for Results

    • Provide a powerful 360 view including profiling, comprehensive interaction history and Rx trends.
    • Create efficient coverage plans for clinic visits with better calendaring and travel expense management.
    • Use in-built knowledge retention to combat effects of sales force attrition.
    • Utilize the waiting time during clinic visits by capturing competitor activities to build market intelligence.

    Organize Conferences with Ease

    • Enhance management of medical events through collaborative planning and execution.
    • Automate the process of sending invitations, confirmations, event reminders and post-meeting gratitude communications through mailing lists and templates.
    • Track the effectiveness of medical events and ROI.

    Improve Complaint Resolution and Compliance

    • Manage all adverse comments and complaints from retailers, physicians and hospitals through a single consolidated repository.
    • Implement multi-department workflows for timely resolution of service requests.
    • Monetize service satisfaction goodwill using ‘Service-to-Sales’ processes
    • Enforce unified TAT across processes; ascertain compliance and accountability by using escalation metrics.

    Reduce Training Costs

    • Centralize and make training programs available to facilitate self-learning
    • Create a secure single destination for all collaterals
    • Create an online knowledge base for frequently asked questions by physicians and chemists during field visits.

    Utilize Advanced Reporting

    • Get real-time reports across teams, products and geographies.
    • Move from fragmented to a unified multi-system collated reporting.
    • Establish an efficient analysis path using drill-down capabilities.
    • Provide actionable insights that aid you in taking key decisions.
    • Boost results by measuring and improving critical performance indicators that contributes to margins.

    Resources

    About CRMNEXT s Pharmaceutical Digital CRM Edition:

    CRMNEXT s Digital CRM for pharmaceuticals is a comprehensive solution that helps pharmaceutical companies in managing relationships with physicians, chemists, hospitals and healthcare societies. In the age of patent expiration pricing scrutiny, pharmaceutical companies are increasingly facing pressure to build stronger relationship management capabilities to help boost prescription share and avoid legal hassles. This is the right time for companies to implement a constant learning model which can identify market shifts and respond effectively, thereby increasing competitive advantage. It also needs a robust platform for KOL management .

    Cloud CRM for pharmaceutical and life sciences have evolved from a workforce management application to a more customer-centric strategy . Current focus in home grown systems and incumbent CRM vendors has failed to keep up with this new realization. Their rigid architecture makes it expensive and obsolete to upgrade. There is a need to review these implementations to ensure that CRM is more aligned with business needs. CRMNEXT provides a fresh way to look at stimulating managing growth. It brings the best practices from over eleven industry verticals in one comprehensive offering.

    CRMnext s CRM software for Pharma and Life Sciences Edition helps companies in addressing the following challenges:

    1. How to quantify physicians’ perception about drugs?
    2. How to ensure optimum utilization of samples?
    3. How to segment chemists and hospitals based on consumption potential and growth prospects?
    4. How to optimize travel plans for sales teams?
    5. How to contain training costs in the face of attrition?
    6. How to record competitor steps to build business intelligence?
    7. How to track and prioritize complaints, including medical defects?
    8. How to provide real-time insights into key performance indicators with intelligent reports and dashboards for pro-active actions?
    9. How to prioritize physicians based on influence Rx habits?

    Large and medium sized pharmaceutical companies can benefit from a high-impact pharma Digital CRM as it ensures the following:

    1. Segmentation on potential growth.
    2. Track competitor s campaigns.
    3. Assignments for cases based on importance and priority.
    4. Prioritization of contact database.
    5. Quantify data for in-depth analysis.
    6. Effective activity management.
    7. Follow-up samples dispatch.
    8. Knowledge management and training.





    Pharma analytics #pharma.org

    #pharma analytics

    #

    Pharmaceuticals

    Few industries combine billion-dollar bets, cutting-edge science, and global impact like pharmaceuticals. Which drugs should we invest in? How can we streamline clinical operations? What are the biggest risks to our products and our portfolio? These big decisions require big insights—and Tableau lets anyone get answers instantly. At major pharma companies around the world, Tableau supports data-driven action from the lab bench to the boardroom. Researchers use it to control the quality of high-volume assays. Decision-makers choose where to invest based on the freshest information. And marketers get a clear picture of results across physicians, prescriptions, sales, and geography.

    Customer Stories

    Examples

    Whitepapers

    This whitepaper examines how innovative pharmaceutical companies are leveraging data in new ways to bring the right drugs to market faster, and with enormous cost savings.

    Choosing the right type of chart or graph visualization can be key to conveying the most important insights in your data—on sight. This paper will help you determine which chart is best for the type of data you’re analyzing and the questions you want to answer.

    But simply casting your data onto a static graph can at best answer simple questions. We’ll go beyond, and teach you about combining graphs on a dashboard, adding filters, and what charts pair well together. From a horizontal bar graph to a box-and-whisker plot, you’ll be slinging graphs at the speed of curiosity. The result.

    This past year was an important one for Big Data. More businesses realized that data, in all forms and sizes, is critical for the best possible decision-making. In support of this, we’ll continue to see the systems that support non-relational or unstructured forms of data, as well as massive data volumes, evolve and mature to operate well inside of Enterprise IT systems. This will enable business users, along with data scientists, to fully realize and unlock the value in big data.

    Each year at Tableau we start a conversation about what’s happening in the industry. This discussion.

    Try Tableau for free

    © 2003-2016 Tableau Software. All Rights Reserved